Browse by Track

ARRO
Saturday, Oct 20
10:00 am

Opening Remarks by the ARRO Executive Committee
Location: Hemisfair Ballroom 3
Jenna Kahn, MD – Virginia Commonwealth University Health System
Saturday, Oct 20
10:00 am

ARRO Annual Seminar - (INTERACTIVE) ARRO Annual Seminar

Location: Hemisfair Ballroom 3
Saturday, Oct 20
10:10 am

Opening Remarks by the ARRO Executive Committee
Location: Hemisfair Ballroom 3
Ashley Albert, MD
Saturday, Oct 20
10:16 am

Global Health Scholar Presentation_1
Location: Hemisfair Ballroom 3
Serguei Castaneda, MD
Saturday, Oct 20
10:22 am

Global Health Scholar Presentation_2
Location: Hemisfair Ballroom 3
Adam Olson, MD, MS
Saturday, Oct 20
10:28 am

Global Health Scholar Presentation_3
Location: Hemisfair Ballroom 3
Sherry Zhao, MD
Saturday, Oct 20
10:34 am

Radiating Hope: Life Outside of Medicine and Adventures in Other Countries
Location: Hemisfair Ballroom 3
Larry Daugherty, MD
Saturday, Oct 20
10:54 am

ROI Presentation-Research for the Future of Our Profession
Location: Hemisfair Ballroom 3
Robert Miller, MD, MBA, FASTRO
Saturday, Oct 20
11:04 am

Financial and Contracts
Location: Hemisfair Ballroom 3
Nikhil Thaker, MD, BS
Saturday, Oct 20
12:04 pm

Breakout Session For Scientist Luncheon, Women, in Radiation Oncology, Finance/contracts small groups
Location: Hemisfair Ballroom 3
Terry Wall, MD, JD, FASTRO – TRI, PA
Saturday, Oct 20
1:04 pm

Radiation Oncology Career Journeys: Vocation, Inspiration, and Rewriting Your C.V
Location: Hemisfair Ballroom 3
Tracy Balboni, MD, MPH – Brigham and Women's Hospital
Saturday, Oct 20
2:19 pm

Applying for Jobs: A Panel Discussion - Moderator
Location: Hemisfair Ballroom 3
Lisa Kachnic, MD, FASTRO – Vanderbilt University Medical Center
Saturday, Oct 20
2:20 pm

Applying For Jobs Panel? - Private Practice
Location: Hemisfair Ballroom 3
Leah Katz, MD
Saturday, Oct 20
2:31 pm

Applying For Jobs Panel - Academic
Location: Hemisfair Ballroom 3
Lindsay Burt, MD
Saturday, Oct 20
2:42 pm

Applying For Jobs Panel - Private Practice
Location: Hemisfair Ballroom 3
Guy Jones, MD
Saturday, Oct 20
2:53 pm

Applying For Jobs Panel - Physician Scientist
Location: Hemisfair Ballroom 3
Aparna Kesarwala, MD, PhD – National Cancer Institute
Saturday, Oct 20
3:05 pm

Educational session: Innovative Radiation Oncology - eContour
Location: Hemisfair Ballroom 3
Erin Gillespie, MD
Saturday, Oct 20
3:35 pm

Educational session: Innovative Radiation Oncology - themednet.org
Location: Hemisfair Ballroom 3
Nadine Housri, MD
Saturday, Oct 20
4:05 pm

Practice Entry Survey Results
Location: Hemisfair Ballroom 3
Terry Wall, MD, JD, FASTRO – TRI, PA
Saturday, Oct 20
6:00 pm

ARRO Reception - ARRO Reception
Sunday, Oct 21
12:15 pm

Topic for 2018
Location: Room 302
Brian Kavanagh, MD, MPH, FASTRO
Sunday, Oct 21
12:15 pm

ARRO Annual Luncheon - ARRO Annual Luncheon

Location: Room 302
Sunday, Oct 21
4:45 pm

ARRO MTP - ARRO Meet the Professor Reception

Location: Room 302
Sunday, Oct 21
4:46 pm

Meet the Professor
Location: Room 302
Laura Dawson, MD, FASTRO – Princess Margaret Hospital
Sunday, Oct 21
4:47 pm

Meet the Professor
Location: Room 302
Nadine Housri, MD
Sunday, Oct 21
4:48 pm

Meet the Professor
Location: Room 302
Joachim Yahalom, MD, FASTRO – Memorial Sloan Kettering Cancer Center
Sunday, Oct 21
4:49 pm

Meet the Professor
Location: Room 302
Jonathan Knisely, MD, FASTRO – Weill Cornell Medical College
Sunday, Oct 21
4:50 pm

Meet the Professor
Location: Room 302
Charles Thomas, MD – Oregon Health and Science University
Sunday, Oct 21
4:51 pm

Meet the Professor
Location: Room 302
Alexander Louie, MD, PhD, MSc, FRCPC – Sunnybrook Health Sciences Centre - Canada
Sunday, Oct 21
4:52 pm

Meet the Professor
Location: Room 302
Colleen Lawton, MD, FASTRO – Medical College of Wisconsin
Sunday, Oct 21
4:53 pm

Meet the Professor
Location: Room 302
Allen Chen, MD – University of Kansas School of Medicine
Sunday, Oct 21
4:54 pm

Meet the Professor
Location: Room 302
Timothy Williams, MD, FASTRO
Sunday, Oct 21
4:55 pm

Meet the Professor
Location: Room 302
Yoshiya Yamada, MD, FRCPC – Memorial Sloan Kettering Cancer Center
Sunday, Oct 21
4:56 pm

Meet the Professor
Location: Room 302
Lawrence Marks, MD, FASTRO
Sunday, Oct 21
4:57 pm

Meet the Professor
Location: Room 302
Matthew Katz, MD, FASTRO
Sunday, Oct 21
4:58 pm

Meet the Professor
Location: Room 302
Terence Sio, MD, MS
Monday, Oct 22
12:15 pm

ARRO Poster Viewing - ARRO Poster Viewing With a Professor

Location: Innovation Hub, Exhibit Hall 3
Monday, Oct 22
12:15 pm

Biology Track
Location: Innovation Hub, Exhibit Hall 3
Brian Marples, PhD – University of Miami
Monday, Oct 22
12:15 pm

Breast Track
Location: Innovation Hub, Exhibit Hall 3
Suzanne Evans, MD – Yale University
Monday, Oct 22
12:15 pm

Central Nervous System Track
Location: Innovation Hub, Exhibit Hall 3
Stephanie Weiss, MD, FASTRO – Fox Chase Cancer Center
Monday, Oct 22
12:15 pm

Education & History in Radiation Oncology Track
Location: Innovation Hub, Exhibit Hall 3
Daniel Golden, MD, MHPE
Monday, Oct 22
12:15 pm

Gastrointestinal Track
Location: Innovation Hub, Exhibit Hall 3
Salma Jabbour, MD – Rutgers Cancer Institute of New Jersey
Monday, Oct 22
12:15 pm

Genitourinary Track
Location: Innovation Hub, Exhibit Hall 3
Bridget Koontz, MD
Monday, Oct 22
12:15 pm

Gynecological Track
Location: Innovation Hub, Exhibit Hall 3
David Gaffney, MD, PhD, FASTRO – University of Utah
Monday, Oct 22
12:15 pm

Head & Neck Track
Location: Innovation Hub, Exhibit Hall 3
Farzan Siddiqui, MD, PhD
Monday, Oct 22
12:15 pm

Lung Track
Location: Innovation Hub, Exhibit Hall 3
Gregory Videtic, MD, CM, FRCPC, FASTRO – Cleveland Clinic
Monday, Oct 22
12:15 pm

Lymphoma Track
Location: Innovation Hub, Exhibit Hall 3
Kenneth Roberts, MD
Monday, Oct 22
12:15 pm

Patient Reported Outcomes/QoL/Survivorship Track
Location: Innovation Hub, Exhibit Hall 3
Ronald Chen, MD, MPH – University of North Carolina
Monday, Oct 22
12:15 pm

Pediatrics Track
Location: Innovation Hub, Exhibit Hall 3
Stephanie Terezakis, MD – Johns Hopkins School of Medicine
Monday, Oct 22
12:15 pm

Sarcoma/Non-malignant
Location: Innovation Hub, Exhibit Hall 3
Yen-Lin Chen, MD – Massachusetts General Hospital
Breast Cancer
Sunday, Oct 21
1:15 pm

eContouring for Breast Cancer

Location: Room 303
Jennifer Bellon, MD, FASTRO – Dana-Farber Cancer Institute
Sunday, Oct 21
1:15 pm

eContouring for Breast Cancer

Location: Room 303
Stephanie Terezakis, MD – Johns Hopkins School of Medicine
Sunday, Oct 21
1:15 pm

eContouring for Breast Cancer

Location: Room 303
Karyn Goodman, MD, MS – University of Colorado Cancer Center
Sunday, Oct 21
1:15 pm

eContouring 05 - eContouring for Breast Cancer

Location: Room 303
Sunday, Oct 21
1:35 pm

eContouring for Breast Cancer

Location: Room 303
Jean Wright, MD – Sibley Memorial Hospital
Sunday, Oct 21
4:45 pm

Axillary surgery considerations in the era of neoadjuvant systemic therapy
Location: Room 214 A/B
Judy Boughey, MD
Sunday, Oct 21
4:45 pm

EDU 04 - (INTERACTIVE) Management of the Axilla and Neoadjuvant Systemic Therapy
Location: Room 214 A/B
Rachel Jimenez, MD
Sunday, Oct 21
5:10 pm

Radiation Considerations in the Era of Neoadjuvant Systemic Therapy
Location: Room 214 A/B
Julia White, MD, FASTRO
Sunday, Oct 21
5:35 pm

Lymphedema and other Quality-Of-Life Considerations after Neoadjuvant Systemic Therapy
Location: Room 214 A/B
Simona Shaitelman, MD, EdM
Sunday, Oct 21
6:00 pm

Audience Q&A
Location: Room 214 A/B
Rachel Jimenez, MD
Monday, Oct 22
10:45 am

83 - A Nomogram for Predicting Lymphedema Risk Following Axillary Surgery and Regional Nodal Irradiation Developed From the NCIC MA.20 Trial
Location: Room 214 C/D
Jeffrey Gross, MD, MS – Northwestern University
Monday, Oct 22
10:45 am

SS 12 - Breast 1 - Toxicity
Location: Room 214 C/D
Dean Shumway, MD – University of Michigan; Matthew Poppe, MD
Monday, Oct 22
10:55 am

84 - NRG Oncology/RTOG 1014: Patient Reported Outcomes (PRO) and Cosmesis From a Phase II Study of Repeat Breast Preserving Surgery and 3D Conformal (3D-CRT) Partial Breast Re-Irradiation (PBrI) for In-Breast Recurrence.
Location: Room 214 C/D
Douglas Arthur, MD, FASTRO – Virginia Commonwealth University
Monday, Oct 22
11:05 am

85 - Reconstruction Failure Rates in Breast Cancer Patients With Two-Stage Expander/Implant Reconstruction Receiving Regional Nodal Irradiation With VMAT: Early Results of a Phase II Trial
Location: Room 214 C/D
Daphna Gelblum, MD, MS – Memorial Sloan Kettering Cancer Center
Monday, Oct 22
11:15 am

86 - Chest Wall Boost in Post-Mastectomy Radiation and the Impact on Reconstruction Complications
Location: Room 214 C/D
George Naoum, MD
Monday, Oct 22
11:25 am

87 - Association Between Radiographic Mastectomy Flap Thickness and Risk of Post-Radiation Therapy Breast Reconstruction Complication
Location: Room 214 C/D
Nitika Paudel, MD, PhD
Monday, Oct 22
11:35 am

88 - Comparing 10 Year Outcomes With Salvage Mastectomy Followed By Immediate Autologous Reconstruction or Tissue Expander/Implant Based Reconstruction in Patients With Locally Recurrent Breast Cancer After Breast Conservation Therapy
Location: Room 214 C/D
Bindu Manyam, MD
Monday, Oct 22
11:45 am

89 - Risk of Radiation Pneumonitis Following Individualized Modern Radiation Therapy With IMRT, a Breath-Holding Technique and Prone Positioning for Breast Cancer
Location: Room 214 C/D
Byung Min Lee, MD
Monday, Oct 22
11:55 am

90 - Comparing 10 Year Outcomes in Radiated Patients With Breast Autologous Reconstruction (AR) or Tissue Expander/Implant Based Reconstruction (TE/I)
Location: Room 214 C/D
Bindu Manyam, MD
Monday, Oct 22
12:05 pm

91 - Comparing Whole Heart Versus Coronary Artery Dosimetry in Predicting the Risk of Cardiac Toxicity Following Breast Radiation Therapy
Location: Room 214 C/D
Sagar Patel, MD – Harvard Radiation Oncology Program
Monday, Oct 22
4:15 pm

Update on the Genomic Profiling of Breast Cancer and Translating Such Research to Clinical Practice
Location: Room 302
Laura Esserman, MD
Monday, Oct 22
4:15 pm

Joint Session 03 (Live SA-CME) - ASTRO-ASCO Joint Session: Genomics to Personalize Breast Cancer Treatment: On the Evolving Road to Minimize Overtreatment
Location: Room 302
Peter Chen, MD, FACR, FASTRO – Oakland University William Beaumont School of Medicine
Monday, Oct 22
4:25 pm

Medical Oncology Therapeutics in the Landscape of Genomic Profiling of Breast Cancer
Location: Room 302
Douglas Yee
Monday, Oct 22
4:45 pm

Breast Surgical Oncology Decision-Making in the Era of Genomic Profiling of Breast Cancer
Location: Room 302
E. Shelley Hwang, MD, MPH
Monday, Oct 22
5:05 pm

Genomic Profiling of Breast Cancer and its Impact on Radiation Oncology Therapeutics
Location: Room 302
Abram Recht, MD, FASTRO
Monday, Oct 22
5:25 pm

Genomic Profiling for Radio-Sensitivity in Radiation Dose Selection for Breast Irradiation
Location: Room 302
Eleanor Harris, MD, FASTRO
Tuesday, Oct 23
7:45 am

132 - Pathogenic Mutations in ATM Enhance Radio-Sensitivity and Local Control in Patients With Primary and Metastatic Breast Cancer
Location: Room 214 A/B
Dana Casey, MD – Memorial Sloan Kettering Cancer Center
Tuesday, Oct 23
7:45 am

SS 21 - Breast 2 - Biology and SBRT
Location: Room 214 A/B
Corey Speers, MD, PhD, BS – University of Michigan; Rachel Blitzblau, MD, PhD
Tuesday, Oct 23
7:55 am

133 - Gene Expression Changes Predict Acute and Late Toxicity to Combined PARP1 Inhibition and Radiation (RT) in High Risk Breast Cancer Patients- Results of the Biomarker Analysis of TBCRC 024
Location: Room 214 A/B
Corey Speers, MD, PhD, BS – University of Michigan
Tuesday, Oct 23
8:05 am

134 - Locoregional Recurrence Is Associated With?Genomic Down-Regulation of the?Immune Response in Women With Locally Invasive Breast Cancer
Location: Room 214 A/B
Casey Liveringhouse, BA – Medical Student
Tuesday, Oct 23
8:15 am

135 - Minimal Increases in Tumor Infiltrating Lymphocytes Despite Excellent Tumor Responses After Pre-Operative Accelerated Partial Breast Irradiation in Early Stage ER+ Breast Cancer Patients
Location: Room 214 A/B
Carmen Bergom, MD, PhD – Medical College of Wisconsin
Tuesday, Oct 23
8:25 am

136 - Phase I Trial of Stereotactic Body Radiation Therapy(SBRT) to Multiple Metastatic Sites: A NRG Oncology Study
Location: Room 214 A/B
Steven Chmura, MD, PhD
Tuesday, Oct 23
8:35 am

137 - Results of a Prospective Cohort Trial: Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy (SIGNAL) for Early-Stage Breast Cancer
Location: Room 214 A/B
Brian Yaremko, MD, MSc, PEng
Tuesday, Oct 23
8:45 am

Scientific Discussant
Location: Room 214 A/B
Stephen Shiao, MD, PhD
Tuesday, Oct 23
1:00 pm

158 - Five-Year Results of a Prospective Phase 2 Trial Evaluating Three-Week Hypofractionated Whole Breast Radiation Therapy with Boost
Location: Room 303
Apar Gupta, MD, MBA
Tuesday, Oct 23
1:00 pm

SS 23 - Breast 3?- General
Location: Room 303
Anthony Dragun, MD – MD Anderson Cancer Center at Cooper; Melissa Mitchell, MD, PhD
Tuesday, Oct 23
1:10 pm

159 - Cancer-Specific Outcomes of Hypofractionated Locoregional Radiation Therapy for Patients With Stage I-III Breast Cancer
Location: Room 303
Theodora Koulis, MD
Tuesday, Oct 23
1:20 pm

160 - Technique and Preliminary Results of a Multi-Center Trial of Intra-Operative Radiation Therapy Using Electronic Brachytherapy at the Time of Breast Conserving Surgery for Early Stage Breast Cancer
Location: Room 303
Alam Syed, MD – LONG BEACH RADIATION ONCOLOGY MEDICAL GROUP
Tuesday, Oct 23
1:30 pm

161 - Salvage Mastectomy Versus Second Conservative Treatment for Second Ipsilateral Breast Tumor Event: A Propensity-Score Matched Cohort Analysis
Location: Room 303
Jean Michel Hannoun Levi, MD, PhD
Tuesday, Oct 23
1:40 pm

162 - Influence of Hypofractionated Radiation Therapy Following Mastectomy on Complication in Breast Cancer Patients Undergoing Two-Stage Prosthetic Breast Reconstruction
Location: Room 303
Jeesuk Chang, MD – Yonsei Cancer Center
Tuesday, Oct 23
1:50 pm

163 - Two-Year Results of Once Daily Accelerated Partial Breast Irradiation: A Randomized Controlled Study
Location: Room 303
Rimoun Boutrus, MD, PhD
Tuesday, Oct 23
2:00 pm

164 - Using Clinical Pathways to Standardize Adoption of Hypofractionated Whole-breast Irradiation for Women Younger Than 50
Location: Room 303
Joshua Rodriguez-Lopez, MD
Tuesday, Oct 23
2:10 pm

165 - Role of Post Mastectomy Radiation Therapy Boost in Invasive Breast Cancer Patients. Is It Needed?
Location: Room 303
Mohamed Abouegylah, MD
Tuesday, Oct 23
2:20 pm

Scientific Discussant
Location: Room 303
Rachel Abrams Rabinovitch, MD, FASTRO – University of Colorado Denver
Tuesday, Oct 23
2:45 pm

TU_1_3323 - Outcomes and Toxicity of Stereotactic Radiation Therapy for Metastatic Breast Cancer - a Retrospective Cohort Study
Location: Innovation Hub, Exhibit Hall 3
Mark Niglas, MD, BS, FRCPC
Tuesday, Oct 23
2:45 pm

TU_1_3324 - The impact of postmastectomy radiation scar boost on local recurrence free survival in high risk patients
Location: Innovation Hub, Exhibit Hall 3
Ashley Albert, MD
Tuesday, Oct 23
2:45 pm

TU_1_3325 - Is Radiation Therapy Dose Escalation for Inflammatory Breast Cancer (IBC) Still Required With Modern Multi-Modality Treatment: A Multi-Institution Retrospective Review, 2000-2011
Location: Innovation Hub, Exhibit Hall 3
Rahul Arora, BS
Tuesday, Oct 23
2:45 pm

TU_1_3326 - Long-Term Results of Post mastectomy Conformal Electron Therapy Technique (PMERT) with bolus in comparison with Post mastectomy Conformal Photon Therapy (PMPhRT) without bolus in non-metastatic breast cancer patients
Location: Innovation Hub, Exhibit Hall 3
Youlia Kirova, MD
Tuesday, Oct 23
2:45 pm

TU_1_3327 - Patterns of Postmastectomy Radiation in Clinically Node Positive Breast Cancer Patients With Pathologically Negative Lymph Nodes After Neoadjuvant Chemotherapy
Location: Innovation Hub, Exhibit Hall 3
John Byun, MD – Cancer Institute of New Jersey
Tuesday, Oct 23
2:45 pm

TU_1_3328 - Characterization of the Tumor Microenvironment (TME) with Quantitative Multiplex Immunofluorescence (qMIF) in a cohort of Neoadjuvant Breast Cancer (BC) patients: a pilot analysis
Location: Innovation Hub, Exhibit Hall 3
Christine Chin, MD
Tuesday, Oct 23
2:45 pm

TU_1_3330 - Analysis of patterns of lymph node metastases in primary and recurrent breast cancer by evaluation of FDG / PET-CT image datasets
Location: Innovation Hub, Exhibit Hall 3
Julia Voppichler, PhD
Tuesday, Oct 23
2:45 pm

TU_1_3331 - Inverse Planning Intensity-Modulated Radiation Therapy in Chest Wall And Lymphatic Irradiation: Early Results
Location: Innovation Hub, Exhibit Hall 3
Melis Gultekin, RT
Tuesday, Oct 23
2:45 pm

TU_1_3332 - Evaluating the Dose to the Lower Posterior Cervical Lymph Nodes and Risk of Supraclavicular Failure in Regional Nodal Irradiation for Breast Cancer Using 3D-Conformal Radiation Therapy and Intensity Modulated Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Erin Healy, MD – The Ohio State University
Tuesday, Oct 23
2:45 pm

TU_1_3398 - Air Expander Implant Can Compromise Target Coverage and Dose Homogeneity of Post-Mastectomy Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Christine Chin, MD
Tuesday, Oct 23
2:45 pm

TU_2_3333 - Comparison of Conventional Dynamic IMRT Plan Versus Target Segmented Plan in Irradiation of Postmastectomy Patients
Location: Innovation Hub, Exhibit Hall 3
Jian Hu, MD
Tuesday, Oct 23
2:45 pm

TU_2_3334 - Effects of Trastuzumab on Locoregional Recurrence in Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Patients Treated With Chemotherapy and Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Seung Hyuck Jeon, MD
Tuesday, Oct 23
2:45 pm

TU_2_3336 - Breast Board Comined with a Thermoplastic Head Mask Immobilization Can Improve the Reproducibility of the Treatment Setup for Breast Cancer Patients Who Received Both Whole Breast and Supraclavicular Nodal Region Irradiation
Location: Innovation Hub, Exhibit Hall 3
Mingwei Ma, MD
Tuesday, Oct 23
2:45 pm

TU_2_3337 - How Should We Proceed With ypN+ Breast Cancer Following Positive Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy?
Location: Innovation Hub, Exhibit Hall 3
Chelsea Miller, MD
Tuesday, Oct 23
2:45 pm

TU_2_3338 - Proton Beam Therapy for Isolated Locoregional Recurrence of Breast Cancer after Mastectomy Without Prior Radiation Therapy: Prospective PCG Registry Analysis
Location: Innovation Hub, Exhibit Hall 3
Joshua Niska, MD
Tuesday, Oct 23
2:45 pm

TU_2_3339 - The Lack of Consensus of International Contouring Guidelines for the Dorsal Border of the Chest Wall Clinical Target Volume: What is the Impact on Organs at Risk and Relationships to Patterns of Recurrence in the Modern-Era?
Location: Innovation Hub, Exhibit Hall 3
Phillip Pifer, MD, PhD – WVU
Tuesday, Oct 23
2:45 pm

TU_2_3340 - Non-metastatic inflammatory breast cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis
Location: Innovation Hub, Exhibit Hall 3
Stephen Shamp, MD
Tuesday, Oct 23
2:45 pm

TU_2_3341 - Early toxicity and patient reported outcomes of post-mastectomy pencil-beam scanning proton therapy in women with immediate tissue expander breast reconstruction
Location: Innovation Hub, Exhibit Hall 3
Na Smith, MD, PhD
Tuesday, Oct 23
2:45 pm

TU_2_3342 - Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach
Location: Innovation Hub, Exhibit Hall 3
Shane Stecklein, MD, PhD
Tuesday, Oct 23
2:45 pm

TU_3_3343 - Survival Outcomes for Breast Cancer Patients with Liver Metastases: A Population-Based Study of 3,549 Patients
Location: Innovation Hub, Exhibit Hall 3
Jaipreet Suri, MD
Tuesday, Oct 23
2:45 pm

TU_3_3344 - Risk factors of locoregional recurrence in patients with N2-3a breast cancer treated with post mastectomy radiation
Location: Innovation Hub, Exhibit Hall 3
Yu Tang, MD
Tuesday, Oct 23
2:45 pm

TU_3_3345 - Uptake of whole breast hypofractionation: a rapid review of the literature
Location: Innovation Hub, Exhibit Hall 3
Matthew Culbert, BS
Tuesday, Oct 23
2:45 pm

TU_3_3346 - Patient Reported Outcomes and Cosmesis Following Once Weekly Hypofractionated Breast Irradiation
Location: Innovation Hub, Exhibit Hall 3
Harriet Eldredge-Hindy, MD
Tuesday, Oct 23
2:45 pm

TU_3_3347 - Multi-institutional Registry Study of Accelerated Partial Breast Irradiation (APBI) Using Non-invasive Image-guided Breast Brachytherapy (NIBB)
Location: Innovation Hub, Exhibit Hall 3
Jaroslaw Hepel, MD
Tuesday, Oct 23
2:45 pm

TU_3_3348 - Short Course, Two Day Accelerated Hypofractionated Partial Breast Balloon Brachytherapy, a Phase II Multi-Institutional Trial
Location: Innovation Hub, Exhibit Hall 3
Jenna Kahn, MD – Virginia Commonwealth University Health System
Tuesday, Oct 23
2:45 pm

TU_3_3349 - A Prospective International Study on Safety and Efficacy of Hypofractionated Radiation Therapy for Post-Operative Breast Cancer Patients in Asian Countries
Location: Innovation Hub, Exhibit Hall 3
Kumiko Karasawa, MD, PhD
Tuesday, Oct 23
2:45 pm

TU_3_3350 - Hypofractionated Regional Nodal Irradiation (HF-RNI) in Early Breast Cancer (BC) after Breast-Conserving surgery (BCS): A single institution comparative study
Location: Innovation Hub, Exhibit Hall 3
Sahar ghith-Neji, MD
Tuesday, Oct 23
2:45 pm

TU_3_3351 - Local Recurrence Rates for Early Stage Breast Cancer Treated With Breast Conservation and Single Fraction IntraOperative Electron Radiation Therapy ( IOERT) at a Community Hospital
Location: Innovation Hub, Exhibit Hall 3
Venita Williams, MD
Tuesday, Oct 23
2:45 pm

TU_3_3379 - Regional Nodal Irradiation (RNI) in the Sentinel Lymph Node Biopsy (SLNB) Era: Comparison of Radiation Therapy (RT) Techniques that Involve Axillary Nodal Levels I-IV
Location: Innovation Hub, Exhibit Hall 3
Sahar ghith-Neji, MD
Tuesday, Oct 23
2:45 pm

TU_4_3353 - Secondary Breast Cancer after DCIS: Impact of Initial Radiation Therapy on Mortality Associated With Invasive Second Breast Cancers
Location: Innovation Hub, Exhibit Hall 3
Puyao Li, MD
Tuesday, Oct 23
2:45 pm

TU_4_3354 - Hypofractionated Partial Breast Irradiation after Breast-conserving Surgery for Patients with Low-risk Breast Cancer: Preliminary Safety Results in initial 50 Cases
Location: Innovation Hub, Exhibit Hall 3
Jinli Ma, MD
Tuesday, Oct 23
2:45 pm

TU_4_3355 - Outcomes in DCIS Patients Treated with Hypofractionated Whole Breast Radiation Therapy With Integrated Boost Compared to Standard Fractionation with Concomitant Boost
Location: Innovation Hub, Exhibit Hall 3
Jonathan Paly, DO
Tuesday, Oct 23
2:45 pm

TU_4_3356 - Improving Reproducibility and Inter-Rater Reliability for Lumpectomy Cavity Boost Contouring in Breast Cancer Patients Using a 3-D Bio-Absorbable Tissue Marker
Location: Innovation Hub, Exhibit Hall 3
Mustafa Abugideiri, MD
Tuesday, Oct 23
2:45 pm

TU_4_3357 - Temporal Trends in the Use of Immediate Oncoplastic Techniques in Women Undergoing Breast Conserving Surgery and Adjuvant Radiation
Location: Innovation Hub, Exhibit Hall 3
Jose Bazan, MD, MS
Tuesday, Oct 23
2:45 pm

TU_4_3358 - Utilization and Toxicity of Breast Boost Radiation Therapy Following Hypofractionated Whole Breast Irradiation: Comparative Analysis of a Large, Statewide Multicenter Cohort
Location: Innovation Hub, Exhibit Hall 3
Thomas Boike, MD
Tuesday, Oct 23
2:45 pm

TU_4_3359 - The optimal adjuvant treatment in older patients with hormone receptor positive early stage breast cancer (BC) is breast radiation (RT) not endocrine therapy (ET)
Location: Innovation Hub, Exhibit Hall 3
Manjeet Chadha, MD, FASTRO – Mount Sinai Beth Israel Medical Center
Tuesday, Oct 23
2:45 pm

TU_4_3360 - Post-Mastectomy Radiation Therapy in Stage II N1 Breast Cancer Patients Is Associated with Improved Survival with Different Sub-Type.
Location: Innovation Hub, Exhibit Hall 3
Wei-Kai Chuang, MD
Tuesday, Oct 23
2:45 pm

TU_4_3361 - Accelerated Partial Breast Irradiation Outcomes from a Tertiary Referral Community Hospital: Utilizing the Guidelines
Location: Innovation Hub, Exhibit Hall 3
Danielle Cunningham, MD
Tuesday, Oct 23
2:45 pm

TU_4_3363 - Increasing use of hypofractionated whole breast irradiation: an analysis of practice patterns within a state-wide quality consortium
Location: Innovation Hub, Exhibit Hall 3
Joshua Dilworth, MD, PhD – Beaumont Health System
Tuesday, Oct 23
2:45 pm

TU_5_3362 - Helical Tomotherapy (HT) for postmastectomy radiation therapy (PMRT) treatment after implant breast reconstruction
Location: Innovation Hub, Exhibit Hall 3
Romain Dejean
Tuesday, Oct 23
2:45 pm

TU_5_3364 - Disease Control and Survival Outcomes for Strut-Adjusted Volume Implant for Early-Stage Breast Cancer in ASTRO Consensus Guidelines Cautionary Groups for Accelerated Partial Breast Irradiation: A Single-Institution Experience
Location: Innovation Hub, Exhibit Hall 3
Kris Duriseti, MD, PhD
Tuesday, Oct 23
2:45 pm

TU_5_3366 - A Phase 2 Study of Hypofractionated Partial Breast Irradiation (HF-PBI) in Women with Early Stage Breast Cancer
Location: Innovation Hub, Exhibit Hall 3
Penny Fang, MD, MBA
Tuesday, Oct 23
2:45 pm

TU_5_3367 - Accelerated Partial Breast Irradiation in Guideline-Defined Suitable and Cautionary Patients
Location: Innovation Hub, Exhibit Hall 3
Kelly Fitzgerald, MD, PhD
Tuesday, Oct 23
2:45 pm

TU_5_3368 - A Prospective Trial to Compare Deep Inspiratory Breath Hold (DIBH) with Prone Breast Irradiation
Location: Innovation Hub, Exhibit Hall 3
Naamit Gerber, MD – NYU Langone Medical Center
Tuesday, Oct 23
2:45 pm

TU_5_3369 - Prospective Study of 3-Fraction Intra-Cavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen
Location: Innovation Hub, Exhibit Hall 3
Krishan Jethwa, MD – Mayo Clinic
Tuesday, Oct 23
2:45 pm

TU_5_3370 - Long-term Subsequent Breast Cancer Risk and Overall Survival in Older Women with Estrogen Receptor Positive Early Stage Breast Cancer Treated in a Community Health Plan
Location: Innovation Hub, Exhibit Hall 3
Deborah Jiang, MD, MS
Tuesday, Oct 23
2:45 pm

TU_5_3371 - Evaluation of the Motion Range using Surface Mapping System during the Deep Inspiration Breath Hold for Left-Sided Breast Cancer Patients
Location: Innovation Hub, Exhibit Hall 3
Wenhuan Jiang, PhD
Tuesday, Oct 23
2:45 pm

TU_5_3372 - The Impact of Disparate Subtypes of Breast Cancer and Response to Postoperative Radiation Therapy in Neoadjuvant Setting
Location: Innovation Hub, Exhibit Hall 3
Kairui Jin, MD
Tuesday, Oct 23
2:45 pm

TU_6_3352 - Accelerated Partial Breast Irradiation with IORT in the Management of DCIS: A Single-Institution Experience in Patient Selection and Treatment Outcomes
Location: Innovation Hub, Exhibit Hall 3
Christine Chin, MD
Tuesday, Oct 23
2:45 pm

TU_6_3373 - A Multicenter Single-arm Confirmatory Trial on Hypofractionated Whole-breast Irradiation after Breast-conserving Surgery
Location: Innovation Hub, Exhibit Hall 3
Yoshifumi Kawaguchi, MD, PhD
Tuesday, Oct 23
2:45 pm

TU_6_3374 - Pre- and Intraoperative Factors Influencing Omission of Planned Intraoperative Radiation Therapy As a Boost for Breast Cancer Patients Undergoing Breast Conserving Treatment
Location: Innovation Hub, Exhibit Hall 3
Jun Won Kim, MD, PhD
Tuesday, Oct 23
2:45 pm

TU_6_3375 - Use of Preoperative Radiation Therapy in Early and Advanced Stage Breast Cancer
Location: Innovation Hub, Exhibit Hall 3
Julie Koenig, BS
Tuesday, Oct 23
2:45 pm

TU_6_3376 - Patterns of Care of Adjuvant Radiation Therapy After Lumpectomy and Survival in T1N0M0 Estrogen Receptor Positive Breast Cancer
Location: Innovation Hub, Exhibit Hall 3
Anna Lee, MD, MPH
Tuesday, Oct 23
2:45 pm

TU_6_3377 - External Validation of IBTR! 2.0 Nomogram for Prediction of Ipsilateral Breast Tumor Recurrence
Location: Innovation Hub, Exhibit Hall 3
Byung Min Lee, MD
Tuesday, Oct 23
2:45 pm

TU_6_3378 - Equivalent Outcomes for Accelerated Partial Breast Irradiation for Invasive Lobular Carcinoma: A Matched Pair Analysis
Location: Innovation Hub, Exhibit Hall 3
Ronald Levitin, MD, BS
Tuesday, Oct 23
2:45 pm

TU_6_3380 - OncotypeDX Risk Stratification in Early Stage Breast Cancer: When is Accelerated Partial Breast Irradiation (APBI) Safe?
Location: Innovation Hub, Exhibit Hall 3
Ashley Newman, MD
Tuesday, Oct 23
2:45 pm

TU_6_3381 - Patient Reported Outcomes From a Prospective Risk-Adapted Breast IORT Registry Trial
Location: Innovation Hub, Exhibit Hall 3
Jane Witter Ridings, MD
Tuesday, Oct 23
2:45 pm

TU_7_3383 - Concordance of Biomarkers and Tumor Location for in-Breast Tumor Recurrences in Early Stage Breast Cancer Patients Treated with Breast Conserving Surgery and Adjuvant RT
Location: Innovation Hub, Exhibit Hall 3
Juhi Purswani, BS
Tuesday, Oct 23
2:45 pm

TU_7_3384 - Once-Weekly Hypofractionated Radiation Therapy in Breast Cancer: A Phase 2 Trial
Location: Innovation Hub, Exhibit Hall 3
Lievin Reboucas, MD, PhD
Tuesday, Oct 23
2:45 pm

TU_7_3385 - Time-Driven Activity-Based Cost Analysis of CT-Guided Intraoperative High-Dose Rate Brachytherapy Versus Whole Breast Irradiation in the Treatment of Early Stage Breast Cancer
Location: Innovation Hub, Exhibit Hall 3
Jason Sanders, MD, BS
Tuesday, Oct 23
2:45 pm

TU_7_3386 - Use of Three-dimensional Ultrasound for Daily Positioning in Patients Treated with Partial Breast Radiation Therapy: Results from a Prospective Clinical Trial
Location: Innovation Hub, Exhibit Hall 3
Mutlay Sayan, MD
Tuesday, Oct 23
2:45 pm

TU_7_3387 - Historical Trends of Implantable Accelerated Partial Breast Irradiation Usage after Breast Conserving Surgery for Stage I Breast Cancer: A SEER Analysis
Location: Innovation Hub, Exhibit Hall 3
Zaid Siddiqui, MD – Beaumont Health System
Tuesday, Oct 23
2:45 pm

TU_7_3388 - Breast Conservation Therapy Achieved Comparable Outcomes with Mastectomy in Patients with T1-2N0 Triple-Negative Breast Cancer: Analysis of 822 Patients in a Single Institution
Location: Innovation Hub, Exhibit Hall 3
Shulian Wang, MD
Tuesday, Oct 23
2:45 pm

TU_7_3389 - Does the Presence of a Bioabsorbable Device Sutured into the Cavity after Breast Conserving Surgery Effect Treatment Planning Targets for Breast Radiation?
Location: Innovation Hub, Exhibit Hall 3
Tamara Smith, MD
Tuesday, Oct 23
2:45 pm

TU_7_3390 - Mastectomy Without Radiation Therapy Had Inferior Outcomes As Compared to Breast Conserving Surgery or Mastectomy Plus Radiation Therapy in Patients With T1-2N1 Triple-Negative Breast Cancer: Analysis of 412 Patients in a Single Institution
Location: Innovation Hub, Exhibit Hall 3
Shulian Wang, MD
Tuesday, Oct 23
2:45 pm

TU_7_3391 - Risk-Adapted Postmastectomy Radiation Therapy for Patients with Clinical T1-2N0-1 Breast Cancer after Neoadjuvant Chemotherapy
Location: Innovation Hub, Exhibit Hall 3
Xin Wang, MD
Tuesday, Oct 23
2:45 pm

TU_7_3392 - Failure to Apply Eligibility Criteria per CALGB 9343 When Omitting Radiation Therapy Results in Excess Locoregional Failures in Elderly Breast Cancer Patients
Location: Innovation Hub, Exhibit Hall 3
Matthew Whitmill, BS
Tuesday, Oct 23
2:45 pm

TU_8_3329 - Post-Mastectomy Radiation Therapy (PMRT) in Women with T3N0 Breast Cancer: An Updated Surveillance, Epidemiology and End Results (SEER) Analysis
Location: Innovation Hub, Exhibit Hall 3
Nicholas Damico, MD
Tuesday, Oct 23
2:45 pm

TU_8_3393 - The Use of New Delineation Tool "MIRADA", Step-by-step Development and First Results of Its Use in Early Stage Breast Cancer Patients
Location: Innovation Hub, Exhibit Hall 3
Haoping Xu, MD, PhD
Tuesday, Oct 23
2:45 pm

TU_8_3394 - The Impact of Adjuvant Radiation Therapy in Elderly Patients with ER Positive, Early Stage Breast Cancer
Location: Innovation Hub, Exhibit Hall 3
George Yang, MD
Tuesday, Oct 23
2:45 pm

TU_8_3395 - A Comparative Study on the Target Volumes Defined Using Preoperative Prone Magnetic Resonance Image and Postoperative Prone Computed Tomography Image Based Deformable Image Registration for External-Beam Partial Breast Irradiation
Location: Innovation Hub, Exhibit Hall 3
Ting Yu
Tuesday, Oct 23
2:45 pm

TU_8_3396 - Re-irradiation of Local-regional Disease in Breast Cancer Using Modern Radiation Techniques: Preliminary Results of Tolerability and Efficacy
Location: Innovation Hub, Exhibit Hall 3
Jose Bazan, MD, MS
Tuesday, Oct 23
2:45 pm

TU_8_3397 - Analyzes of FDG/PET-CT positive Lymph Node Metastases and Implications for Dose Delivery
Location: Innovation Hub, Exhibit Hall 3
Kai Borm, MD
Tuesday, Oct 23
2:45 pm

TU_8_3399 - Malignant and Borderline Phyllodes Tumors of the Breast Treated by Breast-Conserving Surgery Alone: Analysis of the Site and Histologic Grade of Ipsilateral Breast Tumor Recurrences (KROG 16-08)
Location: Innovation Hub, Exhibit Hall 3
Noorie Choi, MD
Tuesday, Oct 23
2:45 pm

TU_8_3400 - Does Deep Inspiration Breath Hold prolong life? Individual Risk Estimates of Ischemic Heart Disease After Breast Cancer Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Stefanie Corradini, MD
Tuesday, Oct 23
2:45 pm

TU_8_3401 - Nationwide Trends in Heart-Sparing Techniques Utilized in Radiation Therapy for Breast Cancer
Location: Innovation Hub, Exhibit Hall 3
Nina Desai, MD
Tuesday, Oct 23
2:45 pm

TU_8_3402 - Radiation Therapy Planning and Phantom Dosimetry of a Novel Breast Tissue Expander
Location: Innovation Hub, Exhibit Hall 3
Benjamin Farnia, MD, BA
Tuesday, Oct 23
2:45 pm

TU_9_3403 - Tattoo Free Set-up for Partial Breast Irradiation: A Feasibility Study
Location: Innovation Hub, Exhibit Hall 3
Rachel Jimenez, MD
Tuesday, Oct 23
2:45 pm

TU_9_3404 - Set-up Reproducibility for Deep Inspiration Breath Hold for Left Sided Breast Cancer Treatment Using Daily Mega Voltage Imaging- Integrated Network Study
Location: Innovation Hub, Exhibit Hall 3
Hayeon Kim, PhD
Tuesday, Oct 23
2:45 pm

TU_9_3405 - Management of loco-regional recurrent breast cancer after prior radiation to the breast or chest wall
Location: Innovation Hub, Exhibit Hall 3
Christine Koch, MD, PhD
Tuesday, Oct 23
2:45 pm

TU_9_3406 - Coronary Calcium Burden in Breast Cancer Patients Receiving Adjuvant Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Yu-Hsuan Lai, MD
Tuesday, Oct 23
2:45 pm

TU_9_3407 - Biologic Subtypes of Primary Breast Tumors Exhibit Differences in the Radiosensitivity Index
Location: Innovation Hub, Exhibit Hall 3
Casey Liveringhouse, BA – Medical Student
Tuesday, Oct 23
2:45 pm

TU_9_3408 - A Reliable Nomogram for Predicting Overall Survival in Patients with Triple-Negative Breast Cancer
Location: Innovation Hub, Exhibit Hall 3
Mingwei Ma, MD
Tuesday, Oct 23
2:45 pm

TU_9_3409 - Assessing Quality of Heart Contouring and Dosimetry in Treatment of Left Sided Breast Cancer Across Cancer Centers within an Integrated Health System
Location: Innovation Hub, Exhibit Hall 3
Bindu Manyam, MD
Tuesday, Oct 23
2:45 pm

TU_9_3410 - What target volume should be considered when irradiating the regional nodes in breast cancer? Results of a network - meta-analysis
Location: Innovation Hub, Exhibit Hall 3
Christiane Matuschek, MD
Tuesday, Oct 23
2:45 pm

TU_9_3411 - Intraoperative Radiation Therapy (IORT) As Sole Adjuvant RT Modality for Breast Cancer: Patterns of Care in the United States and Utilization After Publication of Guidelines and Randomized Trials
Location: Innovation Hub, Exhibit Hall 3
Christopher Morrison, MD, PhD
Tuesday, Oct 23
2:45 pm

TU_9_3412 - Patterns of Care and Predictors of Adjuvant Radiation Therapy in Phyllodes Tumor of the Breast
Location: Innovation Hub, Exhibit Hall 3
Oluwadamilola Oladeru, MD, BS, MA
Tuesday, Oct 23
2:45 pm

TU_10_3413 - Biologic Subtypes as a Predictor of Local Control of Breast Cancer Brain Metastases after Stereotactic Radiosurgery
Location: Innovation Hub, Exhibit Hall 3
Lucas Resende Salgado, MD
Tuesday, Oct 23
2:45 pm

TU_10_3414 - Identifying Survivorship Needs Among Women with Breast Cancer after Receiving Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Kiri Sandler, MD – UCLA
Tuesday, Oct 23
2:45 pm

TU_10_3415 - A Within Subject Study Comparing Utility and Comfort of Breast Board Immobilization with Vacuum Bag for Radiation Therapy in Breast Cancer
Location: Innovation Hub, Exhibit Hall 3
Balu Krishna Sasidharan, MD, MBBS, DNB DMRT
Tuesday, Oct 23
2:45 pm

TU_10_3416 - Internal mammary lymph nodes involvement in patients with breast cancer: anatomical characteristics and implication for target definition
Location: Innovation Hub, Exhibit Hall 3
Yujie Wang
Tuesday, Oct 23
2:45 pm

TU_10_3417 - Pattern of Clavicular Lymph Nodes Metastases and its Implication in Clinical Target Volume Delineation for Patients with Breast Cancer
Location: Innovation Hub, Exhibit Hall 3
Xueqing Zhang, BS
Tuesday, Oct 23
2:45 pm

TU_10_3418 - Acute Toxicity Outcomes and Dosimetric Implications from Incidental Irradiation of Adjacent Tissues in Tangent Field Hypofractionated Breast Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Sara Alcorn, MD, MPH
Tuesday, Oct 23
2:45 pm

TU_10_3419 - Risk of cardiac disease after adjuvant radiation therapy among breast cancer survivors
Location: Innovation Hub, Exhibit Hall 3
Jeesuk Chang, MD – Yonsei Cancer Center
Tuesday, Oct 23
2:45 pm

TU_10_3420 - Long-Term Incidence Rate of Coronary Heart Disease in Breast Cancer Patients - A Population Based Study
Location: Innovation Hub, Exhibit Hall 3
Ying-Hsiang Chou, MD, MBA
Tuesday, Oct 23
2:45 pm

TU_10_3421 - Does Deep Inspiration Breath Hold (DIBH) Impact Dose to Coronary Arteries During Postmastectomy Electron Boost Treatment?
Location: Innovation Hub, Exhibit Hall 3
James Coster, MD
Tuesday, Oct 23
2:45 pm

TU_10_3422 - Comparison of Acute Skin Toxicities in Breast Cancer Patients Undergoing Adjuvant Proton vs. Photon Radiation Therapy: A single institutional experience
Location: Innovation Hub, Exhibit Hall 3
Cristina DeCesaris, MD
Tuesday, Oct 23
2:45 pm

TU_11_3423 - Assessment of Cardiac Dosimetry and Additional Cardiac Risk Factors in Patients Undergoing Modern Breast Cancer Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Christopher Fleming, MD
Tuesday, Oct 23
2:45 pm

TU_11_3424 - A Simple Cardiac Sparing Strategy for Left Breast Radiation Therapy Using Right Semi-Decubitus Positioning
Location: Innovation Hub, Exhibit Hall 3
Claire Fung, MD, MS – Beth Israel Deaconess Medical Center
Tuesday, Oct 23
2:45 pm

TU_11_3425 - Incidence of Breast Lymphedema and Predictors of its Development in Patients Receiving Whole Breast Radiation Therapy Alone after Breast-Conservation Surgery
Location: Innovation Hub, Exhibit Hall 3
Rohit Ganju, MD
Tuesday, Oct 23
2:45 pm

TU_11_3426 - Randomized, Prospective, Open-Label Phase III Trial Comparing β-Sitosterol (mebo) Ointment with Trolamine (biafine) Cream for the Management of Acute Skin Reaction during Radiation Therapy for Breast Cancer
Location: Innovation Hub, Exhibit Hall 3
Fady Geara, MD, PhD
Tuesday, Oct 23
2:45 pm

TU_11_3427 - Palbociclib Enhances Pulmonary Fibrosis in Patients Undergoing Thoracic Radiation Therapy: A Case Series and Review of the Literature
Location: Innovation Hub, Exhibit Hall 3
Ronny Kalash, DO
Tuesday, Oct 23
2:45 pm

TU_11_3428 - Dosimetric Benefits of Continuous Positive Airway Pressure Instead of Free-Breathing during Radiation Therapy for Breast Cancer Patients With Favorable, Unfavorable, and Challenging Cardiac-Thoracic Anatomy
Location: Innovation Hub, Exhibit Hall 3
Whoon Jong Kil, MD
Tuesday, Oct 23
2:45 pm

TU_11_3429 - Increased Risk of Varicella-Zoster Virus Infection in Breast Cancer Patients Treated With Adjuvant Radiation Therapy - A Population Based Cohort Study
Location: Innovation Hub, Exhibit Hall 3
hsin-yi cheng, MD
Tuesday, Oct 23
2:45 pm

TU_11_3430 - Dosimetric Parameters Correlated with Acute and Chronic Toxicity from Single Entry Applicator Accelerated Partial Breast Irradiation
Location: Innovation Hub, Exhibit Hall 3
Hong-yiou Lin, MD, PhD – Beaumont Health
Tuesday, Oct 23
2:45 pm

TU_11_3431 - Novel Hyaluronan Formulation for Preventing Acute Skin Reactions in Breast During Radiation Therapy: A Randomized Clinical Trial
Location: Innovation Hub, Exhibit Hall 3
Osama Mohamad, MD, PhD – UTSW
Tuesday, Oct 23
2:45 pm

TU_11_3432 - Dosimetric Comparison of Deep Inspiration Breath-Hold versus Free Breathing for Right-Sided Breast Cancer with Comprehensive Nodal Radiation
Location: Innovation Hub, Exhibit Hall 3
Ram Narayan, MD
Tuesday, Oct 23
2:45 pm

TU_12_3433 - Comparative Outcome Analysis of Two Dose Schedules for Post-Mastectomy Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Reginald Nguyen, BS
Tuesday, Oct 23
2:45 pm

TU_12_3434 - Nasal Colonization With Staphylococcus Aureus Before Radiation Therapy Predicts Radiation Dermatitis: A Prospective Study
Location: Innovation Hub, Exhibit Hall 3
Alexandra Rzepecki, BS
Tuesday, Oct 23
2:45 pm

TU_12_3435 - The Impact of Chemotherapy on Toxicity and Cosmetic Outcome in Patients Receiving Hypofractionated Whole Breast Irradiation
Location: Innovation Hub, Exhibit Hall 3
Jane Spann, BS
Tuesday, Oct 23
2:45 pm

TU_12_3436 - Changes in Cardiac MRI Derived Left Ventricular Segmental Strain in Left Sided Breast Cancer Patients Treated With Tangential Radioation Therapy Alone Correlated With Dose
Location: Innovation Hub, Exhibit Hall 3
Simon Tang, MD, MBBS
Tuesday, Oct 23
2:45 pm

TU_12_3437 - Proton Beam Therapy Reirradiation for Recurrent Breast Cancer: Multi-Institutional Prospective PCG Registry Analysis
Location: Innovation Hub, Exhibit Hall 3
Cameron Thorpe, MD
Tuesday, Oct 23
2:45 pm

TU_12_3438 - Left Anterior Descending Coronary Artery Dose-Sparing Effects of Volumetric Modulated Arc Therapy in Patients Ineligible for Deep-Inspiration Breath-Hold in Left Breast Radiation Therapy.
Location: Innovation Hub, Exhibit Hall 3
Bartlomiej Tomasik, MD
Tuesday, Oct 23
2:45 pm

TU_12_3439 - Radiation Therapy Significantly Contributes to Loss of Cardiac Function After Treatment for Breast Cancer
Location: Innovation Hub, Exhibit Hall 3
Veerle van den Bogaard, MD
Tuesday, Oct 23
2:45 pm

TU_12_3440 - Radiation effect on late cardiopulmonary toxicity: an analysis comparing DIBH versus prone techniques for breast treatment
Location: Innovation Hub, Exhibit Hall 3
Sherry Yan, MD
Tuesday, Oct 23
4:45 pm

Single-Fraction Upfront Treatment of Breast Cancer
Location: Room 006
Rachel Blitzblau, MD, PhD
Tuesday, Oct 23
4:45 pm

Panel 08 - The Radiobiological Bases of Novel Radiation Treatment Schemes for Breast Cancer
Location: Room 006
Peter Chen, MD, FACR, FASTRO – Oakland University William Beaumont School of Medicine
Tuesday, Oct 23
5:25 pm

Hypofractionation for Whole Breast Irradiation in 5 days (Fast Forward Trial)
Location: Room 006
Adrian Murray Brunt, MBBS, FRCR, FRCP
Tuesday, Oct 23
5:45 pm

The Radiobiology of Innovative Modes of Breast Cancer Treatment: From Tumor Microenvironment to Normal Tissue Effects
Location: Room 006
George Wilson, PhD – William Beaumont Hospital
Wednesday, Oct 24
7:45 am

Scientific Discussant
Location: Room 304
Alice Ho, MD – Cedars Sinai Medical Center
Wednesday, Oct 24
7:45 am

SH 05 - Science Highlights - Breast Cancer
Location: Room 304
Wednesday, Oct 24
11:00 am

Panelist - Medical Oncology Perspective
Location: Room 303
Carlos Barcenas, MD
Wednesday, Oct 24
11:00 am

EDU 38 - (INTERACTIVE) Challenging Cases in the Management of Breast Cancer
Location: Room 303
Gary Freedman, MD
Wednesday, Oct 24
11:17 am

Panelist - Surgical Oncology Perspective
Location: Room 303
E. Shelley Hwang, MD, MPH
Wednesday, Oct 24
11:34 am

Panelist - Radiation Oncology Perspective
Location: Room 303
Abram Recht, MD, FASTRO
Wednesday, Oct 24
11:51 am

Panelist - Radiation Oncology Perspective
Location: Room 303
Catherine Park, MD, FASTRO – University of California, San Francisco
Wednesday, Oct 24
12:08 pm

Panelist - International Radiation Oncology Perspective
Location: Room 303
Yazid Belkacemi, MD, PhD – Henri Mondor Univsrsity Hospital and Faculte de Medecin de Creteil Paris XII
Wednesday, Oct 24
12:25 pm

Audience Q&A
Location: Room 303
Gary Freedman, MD
Wednesday, Oct 24
1:30 pm

1144 - Final Results of Phase I Study of Prophylactic Nipple-Areola Complex Radiation Therapy After Nipple Sparing Mastectomy and Immediate Reconstruction for Breast Cancer or DCIS Patients
Location: Room 217 A/B
Cristiane Takita, MD, MBA
Wednesday, Oct 24
1:30 pm

PD 17 - Breast 4 -Poster Discussion
Location: Room 217 A/B
Wednesday, Oct 24
1:36 pm

1145 - Hypofractionated Radiation is Associated With Less Long-Term Breast Retraction Following Breast Conserving Therapy
Location: Room 217 A/B
Di Wang, BS
Wednesday, Oct 24
1:42 pm

1146 - Postoperative Single-Fraction Partial Breast Irradiation for Low-Risk Stage 0 and I Breast Carcinomas: Results of a Prospective Clinical Trial
Location: Room 217 A/B
William Kennedy, MD
Wednesday, Oct 24
1:48 pm

1147 - The Role of Neo-Bioscore Staging System in Optimizing the Strategies for Regional Nodes Irradiation Following Neoadjuvant Chemotherapy in Breast Cancer Patients With cN1 and ypN0-1
Location: Room 217 A/B
Lu Cao, MD
Wednesday, Oct 24
1:54 pm

1148 - Nomogram-Based Estimate of Axillary Nodal Involvement in ACOSOG Z0011 (Alliance): Validation and Association With Radiation Protocol Variations and Outcomes
Location: Room 217 A/B
Matthew Katz, MD, FASTRO
Wednesday, Oct 24
2:00 pm

1149 - Can Radiation Therapy Be Omitted After Breast Conserving Surgery With or Without Chemotherapy for Older Women (> 70 years old) With Early Stage Triple-Negative Breast Cancer?
Location: Room 217 A/B
Waqar Haque, MD
Wednesday, Oct 24
2:06 pm

1150 - Hypofractionated Whole Breast Irradiation in Large-Breasted Women - Is There A Predictor for Acute Skin Toxicity?
Location: Room 217 A/B
Ankur Patel, MD
Wednesday, Oct 24
2:12 pm

1152 - Outcome and Patterns of Failure in Breast Cancer Patients With FDG-PET Positive Internal Mammary Lymph Nodes: A Multicenter Rare Cancer Network Study
Location: Room 217 A/B
Gamze Ugurluer, MD
Wednesday, Oct 24
2:18 pm

1151 - Prone Partial Breast Irradiation (PBI): Prospective Randomized Trial to Compare Five Versus Three Fractions
Location: Room 217 A/B
Kimberly Thomas
Wednesday, Oct 24
2:24 pm

Scientific Discussant
Location: Room 217 A/B
Simona Shaitelman, MD, EdM
Wednesday, Oct 24
2:37 pm

Scientific Discussant
Location: Room 217 A/B
Mylin Torres, MD – Emory University
Saturday, Oct 20
9:00 am

Introduction
Location: Room 304
Richard Lovett, MD, FASTRO
Saturday, Oct 20
9:00 am

PRO 01 - (INTERACTIVE) PRO - Breast Cancer
Location: Room 304
Richard Lovett, MD, FASTRO – University of Vermont
Saturday, Oct 20
9:05 am

Breast Cancer- To Treat or Not to Treat
Location: Room 304
Jennifer Harper, MD
Saturday, Oct 20
9:30 am

Breast Cancer-Techniques and Volumes of Treatment/ Hypofractionation
Location: Room 304
Jean Wright, MD – Sibley Memorial Hospital
Saturday, Oct 20
9:55 am

Breast Cancer- Post mastectomy treatment and ASTRO Guidelines
Location: Room 304
Gary Freedman, MD
Saturday, Oct 20
10:20 am

Audience Q&A
Location: Room 304
Richard Lovett, MD, FASTRO
Sunday, Oct 21
10:45 am

Meet the Expert - Breast
Location: ASTRO Connect: Breast #423
Abram Recht, MD, FASTRO
Sunday, Oct 21
10:45 am

MTE 12 - Meet The Expert Abram Recht, MD, FASTRO - Breast - Sunday
Sunday, Oct 21
1:45 pm

Meet the Expert - Breast
Location: ASTRO Connect: Breast #423
Julia White, MD, FASTRO
Sunday, Oct 21
1:45 pm

MTE 17 - Meet The Expert Julia White, MD FASTRO - Breast - Sunday
Sunday, Oct 21
4:15 pm

Meet the Expert - Breast
Location: ASTRO Connect: Breast #423
Jennifer Bellon, MD, FASTRO – Dana-Farber Cancer Institute
Sunday, Oct 21
4:15 pm

MTE 22 - Meet The Expert Jennifer Bellon, MD, FASTRO - Breast - Sunday
Monday, Oct 22
11:15 am

MTE 27 - Meet The Expert Atif Khan, PhD - Breast - Monday
Monday, Oct 22
4:15 pm

Meet the Expert - Breast
Location: ASTRO Connect: Breast #423
Rachel Jimenez, MD
Monday, Oct 22
4:15 pm

MTE 32 - Meet The Expert Rachel Jimenez, MD - Breast - Monday
Tuesday, Oct 23
10:45 am

Meet the Expert - Breast
Location: ASTRO Connect: Breast #423
Steven Chmura, MD, PhD
Tuesday, Oct 23
10:45 am

MTE 37 - Meet The Expert Steven Chmura, MD, PhD - Breast - Tuesday
Tuesday, Oct 23
1:30 pm

Meet the Expert - Breast
Location: ASTRO Connect: Breast #423
Corey Speers, MD, PhD, BS – University of Michigan
Tuesday, Oct 23
1:30 pm

MTE 42 - Meet The Experts Corey Speers, MD, PhD, BS and Reshma Jagsi, MD, PhD, FASTRO - Breast - Tuesday
Tuesday, Oct 23
1:52 pm

Meet the Expert - Breast
Location: ASTRO Connect: Breast #423
Reshma Jagsi, MD, PhD, FASTRO – University of Michigan
Tuesday, Oct 23
3:15 pm

Meet the Expert - Breast
Location: ASTRO Connect: Breast #423
Dana Casey, MD – Memorial Sloan Kettering Cancer Center
Tuesday, Oct 23
3:15 pm

MTE 47 - Meet The Experts Dana Casey, MD and Nadeem Riaz, MD, PhD, FASTRO - Breast - Tuesday
Tuesday, Oct 23
4:15 pm

Meet the Expert - Breast
Location: ASTRO Connect: Breast #423
Gary Freedman, MD
Tuesday, Oct 23
4:15 pm

MTE 52 - Meet The Expert Gary Freedman, MD - Breast - Tuesday
Central Nervous System
Sunday, Oct 21
1:15 pm

Indications for WBRT vs. SRS in the Management of Multiple Brain Metastases
Location: Room 304
Eric Chang, MD, FASTRO – Keck School of Medicine of USC
Sunday, Oct 21
1:15 pm

EDU 01 (Live SA-CME) - The Modern Management of Brain Metastases
Location: Room 304
Yoshiya Yamada, MD, FRCPC – Memorial Sloan Kettering Cancer Center
Sunday, Oct 21
1:35 pm

Combining SRS/WBRT with immunotherapy/targeted therapy for brain metastases
Location: Room 304
John Fiveash, MD – University of Alabama Birmingham
Sunday, Oct 21
1:55 pm

Reirradiation of brain metastases; Management of local failures
Location: Room 304
Jonathan Knisely, MD, FASTRO – Weill Cornell Medical College
Sunday, Oct 21
2:15 pm

Indications for Single Fraction vs. Fractionated SRS in the treatment of Brain Metastases
Location: Room 304
Yoshiya Yamada, MD, FRCPC – Memorial Sloan Kettering Cancer Center
Sunday, Oct 21
4:45 pm

1018 - The Diagnosis and Comprehensive Treatment of Leptomeningeal Metastasis: A Phase II Trial
Location: Room 217 A/B
Siran Yang, MD
Sunday, Oct 21
4:45 pm

PD 03 - CNS 1 - Poster Discussion - Toxicity and Quality of Life
Location: Room 217 A/B
Sunday, Oct 21
4:51 pm

1019 - Whole Brain Re-irradiation Using Pulsed Reduced Dose Rate
Location: Room 217 A/B
Adam Burr, MD, PhD
Sunday, Oct 21
4:57 pm

1020 - Early Diffusion Imaging Biomarkers of Prefrontal Lobe White Matter Microstructural Damage are Associated With Executive Dysfunction Following Radiation Therapy in Patients With Primary Brain Tumors: A Prospective, Longitudinal Study
Location: Room 217 A/B
Kathryn Tringale, MD, MS – UCSD School of Medicine
Sunday, Oct 21
5:03 pm

1021 - Impact of Corticosteroids on the Efficacy of Anti-PD-1 Therapy for Tumors Located Within or Outside the Central Nervous System
Location: Room 217 A/B
Russell Maxwell, MD
Sunday, Oct 21
5:09 pm

1022 - Effects of Tumor Treating Fields (TTFields) on Health-Related Quality of Life (HRQoL) in Newly Diagnosed Glioblastoma: An Exploratory Analysis of the EF-14 Randomized Phase III Trial
Location: Room 217 A/B
Steven Toms, MD
Sunday, Oct 21
5:15 pm

1023 - TRAIT (Treatment-Related Alterations In Thinking): A Prospective Longitudinal Study Assessing Mild Cognitive Impairment in Irradiated Brain Tumor Patients
Location: Room 217 A/B
Christina Cramer, MD – Wake Forest Baptist Medical Center
Sunday, Oct 21
5:21 pm

1024 - Dosimetric Predictors of Cognitive Decline in Attention and Processing Speed After Fractionated Brain Radiation Therapy
Location: Room 217 A/B
Minh-Phuong Huynh-Le, MD – University of California, San Diego
Sunday, Oct 21
5:27 pm

1025 - One-Week Chemoradiotherapy is Associated With Less Treatment-Related Lymphopenia Compared to a Standard?Treatment?Course for Newly Diagnosed Glioblastoma
Location: Room 217 A/B
Dylann Fujimoto, BS
Sunday, Oct 21
5:33 pm

1026 - Adverse Radiation Effect following Repeat Stereotactic Radiosurgery for Brain Metastases
Location: Room 217 A/B
Jason Chan, MD – UCSF Radiation Oncology
Sunday, Oct 21
5:52 pm

Scientific Discussant
Location: Room 217 A/B
Mark Stavas, MD
Monday, Oct 22
10:45 am

MO_1_2455 - Quality of Life, Survival, and Recurrence Patterns following Adjuvant Stereotactic Radiosurgery for Resected Brain Metastases
Location: Innovation Hub, Exhibit Hall 3
Jessica Arden, MD, PhD
Monday, Oct 22
10:45 am

MO_1_2458 - Subventricular Zone (SVZ) Radiation Dose and Outcomes in Patients with Glioblastoma Multiforme (GBM)
Location: Innovation Hub, Exhibit Hall 3
Huma Chaudhry, MD
Monday, Oct 22
10:45 am

MO_1_2472 - Interplay of Age and Performance Status on Patterns of Care and Outcomes in Elderly Patients with Glioblastoma: A National Cancer Database Analysis
Location: Innovation Hub, Exhibit Hall 3
Karine Al Feghali, MD, MS
Monday, Oct 22
10:45 am

MO_1_2473 - Stereotactic intracranial ablative radiation therapy for brain metastases with a mono-isocenter no-coplanar dedicated system: A preliminary dosimetric and clinical report
Location: Innovation Hub, Exhibit Hall 3
Filippo Alongi, MD, PROF – Sacro Cuore Don Calabria CANCER CARE CENTER
Monday, Oct 22
10:45 am

MO_1_2478 - Risk of visual toxicity following fractionated proton vs photon radiation therapy for patients with meningiomas
Location: Innovation Hub, Exhibit Hall 3
Andrew Bishop, MD
Monday, Oct 22
10:45 am

MO_1_2481 - A Population-Based Study of Melanoma Brain Metastasis Treatment: Has Progress in Systemic Therapy and Radiation Therapy Improved Patient Outcomes?
Location: Innovation Hub, Exhibit Hall 3
Harry Brastianos, MD, PhD, BS
Monday, Oct 22
10:45 am

MO_1_2483 - Post-operative cavity radiation therapy with standard fractionation for brain metastases
Location: Innovation Hub, Exhibit Hall 3
James Byrne, MD, PhD
Monday, Oct 22
10:45 am

MO_1_2486 - Initial Findings of Analysis of Circulating Tumor Cells in Patients with Brain Metastases of Breast Cancer
Location: Innovation Hub, Exhibit Hall 3
Douglas Castro, MD
Monday, Oct 22
10:45 am

MO_1_2487 - Assessing the Impact of Pre-Treatment White Matter Hyperintensities on Cognitive Function After Whole Brain Radiation Therapy (WBRT)
Location: Innovation Hub, Exhibit Hall 3
Matthew Chan, MD
Monday, Oct 22
10:45 am

MO_1_2488 - Reirradiation of Recurrent High Grade Gliomas: Outcomes and Prognostic Factors
Location: Innovation Hub, Exhibit Hall 3
Christopher Chapman, MD, MS
Monday, Oct 22
10:45 am

MO_2_2492 - Clinical Outcomes and Safety Profile of Salvage External Beam Radiation Therapy and Re-Irradiation for Recurrent Atypical Meningioma
Location: Innovation Hub, Exhibit Hall 3
William Chen, BS
Monday, Oct 22
10:45 am

MO_2_2493 - Extent of Resection Is Potent Prognostic Factor Next to Molecular Pathologic Subtype in Low-Grade Glioma
Location: Innovation Hub, Exhibit Hall 3
Jinhyun Choi, MD
Monday, Oct 22
10:45 am

MO_2_2495 - The effect of low dose radiation on Alzheimer's disease-induced TG mice
Location: Innovation Hub, Exhibit Hall 3
Se young Choi, MS
Monday, Oct 22
10:45 am

MO_2_2496 - Radiosurgery and Checkpoint Blockade Confer Pathologic Complete Response in Mouse Glioblastoma Multiforme with Distinct Immunologic and Radiographic Signatures
Location: Innovation Hub, Exhibit Hall 3
Mariano Clausi, PhD
Monday, Oct 22
10:45 am

MO_2_2497 - A Retrospective Review on Stereotactic Radiosurgery Cases Planned with Dynamic Conformal Arcs Versus Volumetric Modulated Arc Therapy
Location: Innovation Hub, Exhibit Hall 3
Yunfeng Cui, PhD
Monday, Oct 22
10:45 am

MO_2_2498 - Outcomes in BRAF^V600e-mutant melanoma brain metastases managed with radiosurgery: a multi-institutional assessment of craniotomy mitigation
Location: Innovation Hub, Exhibit Hall 3
Salah Dajani, MS
Monday, Oct 22
10:45 am

MO_2_2502 - Ocular Brachytherapy for Intra-ocular Melanoma: Experience and Outcomes in The Province of Alberta
Location: Innovation Hub, Exhibit Hall 3
Deepak Dinakaran, MD, (PhD)
Monday, Oct 22
10:45 am

MO_2_2503 - Consensus Guidelines for Target Volume Definition of the Sacrum in Spinal Stereotactic Body Radiation Therapy (SBRT)
Location: Innovation Hub, Exhibit Hall 3
Emma Dunne, PhD, MBBS, FRCR
Monday, Oct 22
10:45 am

MO_3_2490 - Prognostic and functional characterization of AQP1 and AQP4 in patients with glioma based on TCGA database
Location: Innovation Hub, Exhibit Hall 3
Mei hua Chen, MD
Monday, Oct 22
10:45 am

MO_3_2509 - Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated with anti-PD-1 Therapy
Location: Innovation Hub, Exhibit Hall 3
Muhammad Fareed, MD, FCPS
Monday, Oct 22
10:45 am

MO_3_2514 - Hippocampal sparing preserves neurocognitive functions in patients of Pituitary adenoma treated with IG-IMRT technique.
Location: Innovation Hub, Exhibit Hall 3
Utpal Gaikwad, MD, MBBS
Monday, Oct 22
10:45 am

MO_3_2515 - National Practice Patterns of Proton versus Photon Therapy in the Treatment of Adult Patients with Primary Brain Tumors
Location: Innovation Hub, Exhibit Hall 3
Vaishnavi Ganesan
Monday, Oct 22
10:45 am

MO_3_2520 - Phase II Prospective Trial to Assess the Feasibility and Efficacy of Dynamic 24Gy Single Dose Ablative Stereotactic Radiation Therapy in Oligometastatic Human Cancer
Location: Innovation Hub, Exhibit Hall 3
Carlo Greco, MD, MD
Monday, Oct 22
10:45 am

MO_3_2521 - A Single-Centre Prospective Assessment of Mask Versus Frame Fixation during Gamma Knife Treatment for Brain Metastases
Location: Innovation Hub, Exhibit Hall 3
Mario Grimm
Monday, Oct 22
10:45 am

MO_3_2522 - Safety of Tumor Treating Fields and Concomitant Radiation Therapy for Newly Diagnosed Glioblastoma in a Pilot Study
Location: Innovation Hub, Exhibit Hall 3
Rachel Grossman, MD
Monday, Oct 22
10:45 am

MO_3_2527 - Temporalis Muscle Width as a Measure of Sarcopenia Independently Predicts Overall Survival in Patients with Newly Diagnosed Glioblastoma
Location: Innovation Hub, Exhibit Hall 3
Kristin Hsieh, BA
Monday, Oct 22
10:45 am

MO_3_2529 - Impact of Corticosteroid Use During Chemoradiotherapy on Lymphopenia and Survival of Glioblastoma Patients
Location: Innovation Hub, Exhibit Hall 3
Caressa Hui, BS – Washington University School of Medicine Department of Radiation Oncology
Monday, Oct 22
10:45 am

MO_3_2530 - Atypical histopathological features and the risk of progression/recurrence in WHO grade I-II meningiomas
Location: Innovation Hub, Exhibit Hall 3
William Hwang, MD, PhD – Massachusetts General Hospital
Monday, Oct 22
10:45 am

MO_4_2531 - Elucidation of an Exquisite Synergistic Interaction Between ATR Inhibitors and Alkylating Agents in MGMT-Methylated Glioma cells
Location: Innovation Hub, Exhibit Hall 3
Christopher Jackson, BS
Monday, Oct 22
10:45 am

MO_4_2532 - Evolving National Practice Patterns of Hypofractionated Stereotactic Radiation Therapy Versus Single-Fraction Radiosurgery for Brain Metastases
Location: Innovation Hub, Exhibit Hall 3
Vikram Jairam, MD – Yale-New Haven Hospital
Monday, Oct 22
10:45 am

MO_4_2534 - Stereotactic Radiosurgery for Brain Metastases of Small Cell Lung Cancer at Diagnosis: Local Management Patterns
Location: Innovation Hub, Exhibit Hall 3
Wei Jiang, MD
Monday, Oct 22
10:45 am

MO_4_2535 - Safety and clinical outcomes of ipilimumab and nivolumab plus concurrent stereotactic radiosurgery for brain metastases
Location: Innovation Hub, Exhibit Hall 3
Christopher Johnson, MD, PhD
Monday, Oct 22
10:45 am

MO_4_2541 - Safety, efficacy, and setup accuracy of patients undergoing multi-level spine stereotactic radiosurgery
Location: Innovation Hub, Exhibit Hall 3
William Jackson, MD – University of Michigan
Monday, Oct 22
10:45 am

MO_4_2545 - The Clinical Results of Radiation Therapy for Spinal Cord Ependymoma with Adverse Prognostic Features: A Single-Institution Experience
Location: Innovation Hub, Exhibit Hall 3
Hwa Kyung Byun, MD
Monday, Oct 22
10:45 am

MO_4_2548 - High-dose radiation therapy is needed for intracranial control and long-term survival in patients with non-seminomatous germ cell tumor brain metastases
Location: Innovation Hub, Exhibit Hall 3
Dana Casey, MD – Memorial Sloan Kettering Cancer Center
Monday, Oct 22
10:45 am

MO_4_2549 - A Novel Fractionated Regimen Using Stereotactic Radiosurgery for Trigeminal Neuralgia
Location: Innovation Hub, Exhibit Hall 3
Serguei Castaneda, MD
Monday, Oct 22
10:45 am

MO_4_2558 - Comparison of Treatment Modalities for Large Brain Metastases
Location: Innovation Hub, Exhibit Hall 3
Ammoren Dohm, BS
Monday, Oct 22
10:45 am

MO_4_2559 - Neuroanatomical differences in the brains of cerebral metastasized breast cancer patients:meningeal carcinomatosa patients vs. brain oligometastatic patients vs. multiple metastastic brain patients
Location: Innovation Hub, Exhibit Hall 3
Antonia Reibelt, PhD
Monday, Oct 22
10:45 am

MO_5_2564 - Single Fraction Spine Stereotactic Radiosurgery for Epidural Tumors
Location: Innovation Hub, Exhibit Hall 3
Erinma Elibe, BS
Monday, Oct 22
10:45 am

MO_5_2572 - Estimated Increase in Mean Lifetime Survival for Glioblastoma Patients Age 65 Years and Older Treated with Tumor Treating Fields and Temozolomide Compared to Patients Treated with Temozolomide Alone
Location: Innovation Hub, Exhibit Hall 3
Gregory Guzauskas, PhD
Monday, Oct 22
10:45 am

MO_5_2578 - A Novel Three Dimensional Conformal Radiation Therapy Technique to Decrease the Mean Parotid Gland Dose in Whole Brain Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Lara Hilal, MD
Monday, Oct 22
10:45 am

MO_5_2580 - Dose-Reduced Stereotactic Radiosurgery for Brain Metastases in the Era of CNS-Penetrating Systemic Therapies
Location: Innovation Hub, Exhibit Hall 3
Andrew Huang, MD
Monday, Oct 22
10:45 am

MO_5_2583 - Proton beam re-irradiation as salvage therapy for recurrent intracranial meningiomas
Location: Innovation Hub, Exhibit Hall 3
Brandon Imber, MD, MS
Monday, Oct 22
10:45 am

MO_5_2584 - Defining an Intermediate Risk Group for Low Grade Glioma. An Analysis of the National Cancer Database
Location: Innovation Hub, Exhibit Hall 3
Vikram Jairam, MD – Yale-New Haven Hospital
Monday, Oct 22
10:45 am

MO_5_2589 - Stereotactic radiosurgery for hemorrhagic brain metastases from malignant melanoma
Location: Innovation Hub, Exhibit Hall 3
Kristine Bauer-Nilsen, MD, BS
Monday, Oct 22
10:45 am

MO_5_2799 - Clinical Outcomes of Reirradiation in IDH-mutant Astrocytomas and 1p/19q Codeleted Oligodendrogliomas
Location: Innovation Hub, Exhibit Hall 3
Soumon Rudra, MD
Monday, Oct 22
10:45 am

MO_6_2597 - Outcomes for advanced melanoma with brain metastases treated with stereotactic radiosurgery (SRS) with and without anti-PD1/PDL1 therapy
Location: Innovation Hub, Exhibit Hall 3
Nima Harandi, MD
Monday, Oct 22
10:45 am

MO_6_2602 - Evolution in the Role of Stereotactic Radiosurgery in Patients with Multiple Brain Metastases: An International Survey
Location: Innovation Hub, Exhibit Hall 3
Sunil Dutta, MD
Monday, Oct 22
10:45 am

MO_6_2603 - Improved Outcomes With Adjuvant Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiation Therapy for Resected Intracranial Metastases
Location: Innovation Hub, Exhibit Hall 3
David Francis, MD
Monday, Oct 22
10:45 am

MO_6_2605 - Toxicity and Local Control Outcomes for Brain Metastases Managed with Resection and Aggressive Reirradiation after Initial Radiosurgery Failure
Location: Innovation Hub, Exhibit Hall 3
Brock Baker, MD
Monday, Oct 22
10:45 am

MO_6_2609 - Predictors for and Clinical Impact of Time between Surgical Resection and Radiation Therapy in Glioblastoma: Analysis of the National Cancer Database
Location: Innovation Hub, Exhibit Hall 3
Samantha Buszek, MD
Monday, Oct 22
10:45 am

MO_6_2616 - Treatment of Multiple Brain Metastases Using Single Isocentric Technique with Forward Planned Dynamic Arcs
Location: Innovation Hub, Exhibit Hall 3
Deborah Jiang, MD, MS
Monday, Oct 22
10:45 am

MO_6_2619 - Clinical Outcomes for Primary Parenchymal Tumor of Intermediate Differentiation
Location: Innovation Hub, Exhibit Hall 3
Behnood Khodayari, MD, MS – Kaiser Permanente Los Angeles Medical Center
Monday, Oct 22
10:45 am

MO_6_2621 - Initial clinical and advanced imaging outcomes from a multi-institutional phase I dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases
Location: Innovation Hub, Exhibit Hall 3
Michelle Kim, MD
Monday, Oct 22
10:45 am

MO_6_2622 - Validation and optimization of a web-based nomogram for predicting survival of patients with newly diagnosed glioblastoma
Location: Innovation Hub, Exhibit Hall 3
Nalee Kim, MD
Monday, Oct 22
10:45 am

MO_6_2623 - Single-Isocenter, Volumetric Modulated Arc Radiosurgery for Multiple Brain Metastases in a Single Session
Location: Innovation Hub, Exhibit Hall 3
Joshua Petit, MD
Monday, Oct 22
10:45 am

MO_7_2625 - Spine stereotactic radiosurgery offers excellent local control in patients with bulky spinal disease
Location: Innovation Hub, Exhibit Hall 3
Farasat Kazmi, MB, MS
Monday, Oct 22
10:45 am

MO_7_2629 - HER2 Status and Long Term Local Control Following SRS for Breast Cancer Brain Metastases
Location: Innovation Hub, Exhibit Hall 3
Naren Ramakrishna, MD, PhD
Monday, Oct 22
10:45 am

MO_7_2630 - Safety profile of tumor treating fields in adult glioblastoma patients with implanted non-programmable shunts, programmable shunts, and pacemakers/defibrillators: 6-year updated retrospective analysis
Location: Innovation Hub, Exhibit Hall 3
Yvonne Kew, MD, PhD
Monday, Oct 22
10:45 am

MO_7_2631 - Stereotactic Radiosurgery with Concurrent HER2-directed Therapy is Associated with Improved Objective Response for Breast Cancer Brain Metastasis
Location: Innovation Hub, Exhibit Hall 3
Joseph Kim, BA – Case Western Reserve University School of Medicine
Monday, Oct 22
10:45 am

MO_7_2635 - Results of Hypofractionated Stereotactic Radiation Therapy (HSRT) for Large Brain Metastases and Resection Cavities
Location: Innovation Hub, Exhibit Hall 3
Naren Ramakrishna, MD, PhD
Monday, Oct 22
10:45 am

MO_7_2637 - Stereotactic Radiosurgery (SRS) for Vestibular Schwannoma: Longitudinal Audiologic Assessment in Single and Fractionated Treatments.
Location: Innovation Hub, Exhibit Hall 3
Mohamed Khattab, MD
Monday, Oct 22
10:45 am

MO_7_2638 - Time sequential changes of epithelial-mesenchymal transition signaling induced by ionizing radiation using next-generation sequencing in glioblastoma
Location: Innovation Hub, Exhibit Hall 3
Yi-Jun Kim, MD
Monday, Oct 22
10:45 am

MO_7_2640 - Improved Local Control with Internal Dose-Escalation for Melanoma Brain Metastases Treated with Stereotactic Radiosurgery
Location: Innovation Hub, Exhibit Hall 3
William Kennedy, MD
Monday, Oct 22
10:45 am

MO_7_2641 - Stereotactic Radiosurgery for Vestibular Schwannoma: Longitudinal Radiographic Outcomes Single and Fractionated Treatments.
Location: Innovation Hub, Exhibit Hall 3
Mohamed Khattab, MD
Monday, Oct 22
10:45 am

MO_7_2896 - Metalloproteinase inhibitor 4 to vascular endothelial growth factor A ratio is a prognostic factor of chemoradiation in glioblastoma
Location: Innovation Hub, Exhibit Hall 3
Weir Chiang You, MD, PhD
Monday, Oct 22
10:45 am

MO_8_2644 - The use of anti-PD1 therapy in melanoma patients with known brain metastases: Survival, durable intracranial progression free survival and radionecrosis
Location: Innovation Hub, Exhibit Hall 3
Rifaquat Rahman, MD, BA
Monday, Oct 22
10:45 am

MO_8_2645 - Adverse Radiation Effect and Disease Control in Patients Undergoing Concurrent Stereotactic Radiosurgery and Immunotherapy for Brain Metastases
Location: Innovation Hub, Exhibit Hall 3
Julie Koenig, BS
Monday, Oct 22
10:45 am

MO_8_2651 - Edema or Margin in Glioblastoma CTV Impact on Pattern of Recurrence and Survival of Two Different CTV Delineations Independently Peer Reviewed.
Location: Innovation Hub, Exhibit Hall 3
Ciro Mazzarella, MD
Monday, Oct 22
10:45 am

MO_8_2662 - Oligodendroglioma Patients with 1p/19q Co-deletion Treated with Early or Delayed Radiation Therapy over the Last Two Decades: A Multi-institutional Report
Location: Innovation Hub, Exhibit Hall 3
Alexander Lin, MD, PhD
Monday, Oct 22
10:45 am

MO_8_2668 - Helical Tomotherapy for Whole- Brain Irradiation With Integrated Boost to Multiple Brain Metastases: Dosimetric Analysis and Clinical Outcomes
Location: Innovation Hub, Exhibit Hall 3
Yuchao Ma, MD
Monday, Oct 22
10:45 am

MO_8_2671 - Impact of Distance from Isocenter on Local Control when utilizing Single Isocenter Frameless VMAT SRS for Intact Brain Metastases
Location: Innovation Hub, Exhibit Hall 3
Samuel Marcrom, MD – University of Alabama Birmingham
Monday, Oct 22
10:45 am

MO_8_2674 - Hippocampal avoidance in Whole Brain Radiation Therapy for Metastases - Comparative Neurocognitive and Dosimetric Assessment
Location: Innovation Hub, Exhibit Hall 3
Vibhay Pareek, DR
Monday, Oct 22
10:45 am

MO_8_2675 - Outcome analysis and impact of prognostic factors on survival of 111 Adult Medulloblastoma patients : A long term single institutional study.
Location: Innovation Hub, Exhibit Hall 3
Roshankumar Patil, MD, MBBS
Monday, Oct 22
10:45 am

MO_8_2676 - Concurrent Immunotherapy Usage and Asymmetric Growth May Distinguish True Progression from Treatment Effect in Growing Brain Metastases after Stereotactic Radiosurgery
Location: Innovation Hub, Exhibit Hall 3
Luke Peng, MD, MS
Monday, Oct 22
10:45 am

MO_8_2677 - Neurological death is common in patients with EGFR mutant non-small cell lung cancer
Location: Innovation Hub, Exhibit Hall 3
Matthew Ramotar, BS
Monday, Oct 22
10:45 am

MO_9_2681 - A Multicenter Prospective Cohort Study Evaluating Quality of Life after Radiation or Surgery for Potentially Unstable Spinal Metastases
Location: Innovation Hub, Exhibit Hall 3
Arjun Sahgal, MD – Sunnybrook Health Sciences Centre
Monday, Oct 22
10:45 am

MO_9_2683 - Potential Prognostic Markers for Survival and Neurologic Death in Patients with Breast Cancer Brain Metastases who receive upfront SRS Alone
Location: Innovation Hub, Exhibit Hall 3
Rachel Shenker, BS
Monday, Oct 22
10:45 am

MO_9_2684 - Dosimetric Comparison of Volumetric Modulated Arc Therapy Versus 3-Dimensional Conformal Radiation Therapy in Post-Operative Patients of High Grade Glioma
Location: Innovation Hub, Exhibit Hall 3
Harikesh Bahadur Singh, MD
Monday, Oct 22
10:45 am

MO_9_2690 - Outcomes Following Definitive Single Fraction Stereotactic Radiosurgery for Larger Brain Metastases
Location: Innovation Hub, Exhibit Hall 3
Fabio Ynoe Moraes, MD
Monday, Oct 22
10:45 am

MO_9_2696 - A Contour-Based Approach for Predicting Corneal Toxicity in Patients with Uveal Melanoma Treated with Proton Therapy
Location: Innovation Hub, Exhibit Hall 3
Howard Lee, BA
Monday, Oct 22
10:45 am

MO_9_2698 - Survival Effect Difference of Whole-Brain Radiation Therapy and TKIs in Patients with Brain Metastases from Non-Small Cell Lung Cancer Stratified by EGFR Mutation Status
Location: Innovation Hub, Exhibit Hall 3
Zhensheng Li, MD, PhD
Monday, Oct 22
10:45 am

MO_9_2702 - The Effect of Debulking Surgery on Brainstem Dosimetry and Toxicity for Large Vestibular Schwannomas Treated with Fractionated Stereotactic Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Matthew Mallory, MD
Monday, Oct 22
10:45 am

MO_9_2703 - Correlation of Magnetic Resonance Imaging Apparent Diffusion Coeffecient Values with Treatment Outcome in High Grade Glioma Patients Undergoing Concurrent Chemoradiation
Location: Innovation Hub, Exhibit Hall 3
Vikram Manoor Maiya, MD
Monday, Oct 22
10:45 am

MO_9_2707 - Clinical, Dosimetric, and Radiographic Predictors of Local Failure Following Stereotactic Radiosurgery for Melanoma Brain Metastases
Location: Innovation Hub, Exhibit Hall 3
Adrianna Masters, MD, PhD
Monday, Oct 22
10:45 am

MO_9_2736 - Survival and Prognostic Factors in Patients with Gastrointestinal Cancers and Brain Metastases
Location: Innovation Hub, Exhibit Hall 3
William Breen, MD
Monday, Oct 22
10:45 am

MO_10_2709 - Nationwide Characteristics of Providers Utilizing Tumor Treating Fields for Newly Diagnosed Glioblastoma
Location: Innovation Hub, Exhibit Hall 3
Shearwood McClelland, MD
Monday, Oct 22
10:45 am

MO_10_2710 - Tumor Cavity Recurrence after Stereotactic Radiosurgery of Surgically Resected Brain Metastases: Implication of Deviations from Contouring Guidelines
Location: Innovation Hub, Exhibit Hall 3
David McDermott, MD
Monday, Oct 22
10:45 am

MO_10_2712 - Daily Tracking with MRI-Guided Radiation Therapy of Glioblastoma Resection Cavity and Cerebral Edema Volumes
Location: Innovation Hub, Exhibit Hall 3
Shahil Mehta, BS
Monday, Oct 22
10:45 am

MO_10_2714 - Radiation-induced edema after single or multi-fraction stereotactic radiosurgery (SRS) for non-base of skull (non-BOS) meningioma: A pooled analysis
Location: Innovation Hub, Exhibit Hall 3
Michael Milano, MD, PhD
Monday, Oct 22
10:45 am

MO_10_2715 - Early Objective Response as a Prognosticator for Final Objective Response and Survival following SRS for Brain Metastases Treated with Concurrent Systemic Therapy
Location: Innovation Hub, Exhibit Hall 3
Joseph Kim, BA – Case Western Reserve University School of Medicine
Monday, Oct 22
10:45 am

MO_10_2717 - Outcomes of uveal melanoma with distant metastasis at initial staging: Impact of primary tumor therapy
Location: Innovation Hub, Exhibit Hall 3
Leslie Modlin, MD
Monday, Oct 22
10:45 am

MO_10_2718 - Point-of-care local failure and overall survival prediction models for meningioma
Location: Innovation Hub, Exhibit Hall 3
Olivier Morin, PhD
Monday, Oct 22
10:45 am

MO_10_2721 - Patient Factors Predicting Intracranial Progression: Optimizing MRI Surveillance Interval Following Brain Metastases SRS
Location: Innovation Hub, Exhibit Hall 3
Brahma Natarajan, BS
Monday, Oct 22
10:45 am

MO_10_2722 - Risk Factors for Early Cognitive Deterioration after Whole-Brain Radiation Therapy for Brain Metastasis
Location: Innovation Hub, Exhibit Hall 3
Toshimichi Nakano, MD
Monday, Oct 22
10:45 am

MO_11_2691 - Pretreatment Texture Analysis of Routine Magnetic Resonance Images and Shape Analysis of the Diffusion Tensor predict Volumetric Response after Radiosurgery for Meningiomas
Location: Innovation Hub, Exhibit Hall 3
Herwin Speckter, MS
Monday, Oct 22
10:45 am

MO_11_2727 - Dosimetric Impact of Cesium 131 Seed Migration in Collagen Carrier Brain Brachytherapy Implants
Location: Innovation Hub, Exhibit Hall 3
Dilini Pinnaduwage, PhD
Monday, Oct 22
10:45 am

MO_11_2729 - Genomic Copy Number Gains of ErbB Family Members Predict Poor Clinical Outcomes in Glioma Patients
Location: Innovation Hub, Exhibit Hall 3
Liu Rui
Monday, Oct 22
10:45 am

MO_11_2730 - Timing and Sequence of Chemoradiation for Low-Grade Gliomas Meeting RTOG 9802 Criteria
Location: Innovation Hub, Exhibit Hall 3
Jeff Ryckman, MD, MSMP
Monday, Oct 22
10:45 am

MO_11_2735 - Efficacy and Safety of Hypofractionated Stereotactic Radiosurgery for Perioptic Lesions
Location: Innovation Hub, Exhibit Hall 3
Herwin Speckter, MS
Monday, Oct 22
10:45 am

MO_11_2737 - Treatment-Induced Increase in Eosinophil Count is Associated With Improved Overall Survival in Glioblastoma patients
Location: Innovation Hub, Exhibit Hall 3
Catherine Spina, MD, PhD
Monday, Oct 22
10:45 am

MO_11_2738 - Low dose Bevacizumab in treatment of radiation necrosis post IGRT with Cyberknife boost with Temozolamide for Glioma patients
Location: Innovation Hub, Exhibit Hall 3
Papaiah Susheela Sridhar, MD
Monday, Oct 22
10:45 am

MO_11_2741 - Modern Re-irradiation Versus Post-Bevacizumab Salvage Chemotherapy in Treating Recurrent High-Grade Gliomas
Location: Innovation Hub, Exhibit Hall 3
John Lee, BS
Monday, Oct 22
10:45 am

MO_11_2745 - Radiation-induced vascular malformations mimicking tumor in MRI-based treatment response assessment maps (TRAMs)
Location: Innovation Hub, Exhibit Hall 3
Yael Mardor, PhD
Monday, Oct 22
10:45 am

MO_11_2746 - Spine stereotactic radiosurgery in the treatment of metastatic pheochromocytoma: an updated case series
Location: Innovation Hub, Exhibit Hall 3
Shane Mesko, MD, MBA
Monday, Oct 22
10:45 am

MO_12_2760 - Do Tumor PD-L1 Expression and Neutrophil to Lymphocyte Ratio Influence the Efficacy of Stereotactic Radiosurgery for Brain Metastases from Non-Small Cell Lung Cancer?
Location: Innovation Hub, Exhibit Hall 3
Abimbola Orisamolu, MD
Monday, Oct 22
10:45 am

MO_12_2761 - Clinical Outcome of Brainstem Glioma Treated With or Without Concurrent Chemoradiotherapy: An Institutional Retrospective Analysis of 71 Patients
Location: Innovation Hub, Exhibit Hall 3
Goura Rath, MD
Monday, Oct 22
10:45 am

MO_12_2764 - Outcomes following Stereotactic Radiation (SRS/SRT) plus Surgery versus SRS/SRT Alone for Single or Solitary Metastasis in Patients with Controlled Systemic Disease: A Single-Institution Study
Location: Innovation Hub, Exhibit Hall 3
Nayan Lamba, BA
Monday, Oct 22
10:45 am

MO_12_2766 - Radiosurgery outcome related to chemotherapy association in relapsed glioblastoma multiforme.
Location: Innovation Hub, Exhibit Hall 3
Luis Larrea, MD, PhD
Monday, Oct 22
10:45 am

MO_12_2767 - The Role of High B-Value Diffusion MRI in the Molecular Classification of Lower Grade Gliomas
Location: Innovation Hub, Exhibit Hall 3
Anna Laucis, MD, MPhil
Monday, Oct 22
10:45 am

MO_12_2768 - Impact of Diabetes Mellitus and Metformin on Clinical Outcomes of Brain Metastasis Patients Treated With Stereotactic Radiosurgery
Location: Innovation Hub, Exhibit Hall 3
Michael LeCompte, MS
Monday, Oct 22
10:45 am

MO_12_2778 - Stereotactic Body Radiation Therapy is an Effective and Safe Treatment for Benign Spinal Tumors
Location: Innovation Hub, Exhibit Hall 3
Shane Lloyd, MD, PhD
Monday, Oct 22
10:45 am

MO_12_2781 - Role of Hypofractionated Radiation Therapy in a Multidisiplinary Approach to Treat Persistent Cushing's Disease
Location: Innovation Hub, Exhibit Hall 3
Rasim Meral, MD, PhD
Monday, Oct 22
10:45 am

MO_12_2786 - Comparison of Local Failure and Radionecrosis According to Dose Prescription for Small to Medium Sized Brain Metastasis treated with Radiosurgery
Location: Innovation Hub, Exhibit Hall 3
Fabio Ynoe Moraes, MD
Monday, Oct 22
10:45 am

MO_12_2787 - Local failure and radionecrosis following single fraction stereotactic radiosurgery for surgical cavities from brain metastases
Location: Innovation Hub, Exhibit Hall 3
Fabio Ynoe Moraes, MD
Monday, Oct 22
10:45 am

MO_13_2506 - Radiation-induced White Matter Injury Following Radiation Therapy in Glioblastoma patients
Location: Innovation Hub, Exhibit Hall 3
Hesham Elhalawani, MD, MS
Monday, Oct 22
10:45 am

MO_13_2563 - Investigating Semi-Quantitative in-Vivo Spatial and Dosimetric Analytical Algorithms to Report GBM Patterns of Failures Following Chemoradiation in the IMRT Era
Location: Innovation Hub, Exhibit Hall 3
Hesham Elhalawani, MD, MS
Monday, Oct 22
10:45 am

MO_13_2792 - Effect of Whole Brain Radiation Therapy on the Absolute Brain Volume Loss
Location: Innovation Hub, Exhibit Hall 3
Lindsy Pang, BS
Monday, Oct 22
10:45 am

MO_13_2794 - Report of Neurotoxicity after Concurrent Whole Brain Radiation Therapy and Checkpoint Blockade Immunotherapy for Patients with Brain Metastases
Location: Innovation Hub, Exhibit Hall 3
Robert Press, MD
Monday, Oct 22
10:45 am

MO_13_2800 - Examining Computerized Neurocognitive Screening Test in Predicting Cerebral Progression Free Survival in Patients Undergoing Brain Stereotactic Radiation Therapy for Brain Metastases: A Pilot Study
Location: Innovation Hub, Exhibit Hall 3
Emmanuelle Reygagne
Monday, Oct 22
10:45 am

MO_13_2801 - Effectiveness of Repeat Courses of Stereotactic Radiosurgery in Patients with Brain Metastases: A Single Institution Experience
Location: Innovation Hub, Exhibit Hall 3
Anurag Saraf, MD
Monday, Oct 22
10:45 am

MO_13_2804 - Investigating nationwide usage trends and relative efficacy of combined modality treatments for elderly glioblastoma patients
Location: Innovation Hub, Exhibit Hall 3
Deborah Smith, BS
Monday, Oct 22
10:45 am

MO_13_2805 - Evaluating Nationwide Practice Patterns in Chemoradiotherapeutic Regimens and Relative Efficacy of Chemoradiation Versus Adjuvant Radiation for Grade III Gliomas
Location: Innovation Hub, Exhibit Hall 3
Deborah Smith, BS
Monday, Oct 22
10:45 am

MO_13_2806 - Severe lymphopenia after chemoradiation treatment is associated with worse survival in patients with newly diagnosed GBM
Location: Innovation Hub, Exhibit Hall 3
Andrew Song, MD
Monday, Oct 22
10:45 am

MO_14_2807 - Stereotactic Radiosurgery (SRS) with Immune Checkpoint Inhibitor Therapy (ICI) for Patients with Brain Metastasis (BM): The Impact of Timing and Sequencing
Location: Innovation Hub, Exhibit Hall 3
Rupesh Kotecha, MD
Monday, Oct 22
10:45 am

MO_14_2809 - Is Risk Group-Adapted Adjuvant Radiation Therapy Beneficial for WHO Grade I/II Skull Base Meningioma? a Propensity Score-Matched Analysis
Location: Innovation Hub, Exhibit Hall 3
Sangjoon Park, MD – Yonsei University Health System
Monday, Oct 22
10:45 am

MO_14_2812 - Single Fraction and Fractionated Radiosurgery for Treatment of Brainstem Metastases
Location: Innovation Hub, Exhibit Hall 3
Paul Koffer, MD
Monday, Oct 22
10:45 am

MO_14_2813 - Automatic Contour Propagation of Organs-at-Risk on Serial MRIs and Dosimetric Implications in Glioblastoma Patients Undergoing Chemo-Radiation
Location: Innovation Hub, Exhibit Hall 3
Sangjune Lee, MD, MS, BS
Monday, Oct 22
10:45 am

MO_14_2814 - Whole-Brain Radiation Therapy Plus Sequential or Simultaneous Integrated Boost for the Treatment of Finite Number of Brain Metastases in Non-Small Cell Lung Cancer
Location: Innovation Hub, Exhibit Hall 3
Dai Yuan Ma, MD
Monday, Oct 22
10:45 am

MO_14_2817 - Initial Response Lag time in Flat versus Non-Flat beam frameless Image Guided Trigeminal Radiosurgery
Location: Innovation Hub, Exhibit Hall 3
Vangipuram Shankar, MD
Monday, Oct 22
10:45 am

MO_14_2818 - Consensus Radiation Therapy Contouring Guidelines for Glioblastoma, Based on NRG Recommendations
Location: Innovation Hub, Exhibit Hall 3
Tim Kruser, MD – Northwestern Memorial Hospital
Monday, Oct 22
10:45 am

MO_14_2819 - Comparative Utilization Analysis of Radiation Modalities Among Adults with Primary Brain Tumors in the United States from 2004 to 2015
Location: Innovation Hub, Exhibit Hall 3
Ed Marchan, MD
Monday, Oct 22
10:45 am

MO_14_2820 - Improved Overall and Cause-Specific Survival for Melanoma Brain metastasis Patients Treated with Stereotactic Radiosurgery and Immunotherapy
Location: Innovation Hub, Exhibit Hall 3
Steven Nguyen, MD, BS
Monday, Oct 22
10:45 am

MO_14_2823 - SBRT for spine lesions: A novel optimized delivery technique
Location: Innovation Hub, Exhibit Hall 3
Daniel Saenz, PhD
Monday, Oct 22
10:45 am

MO_15_2827 - Endocrine Remission after Pituitary Stereotactic Radiosurgery:Differences in Rates of Response for Matched Cohorts of Cushing's Disease and Acromegaly Patients
Location: Innovation Hub, Exhibit Hall 3
Sunil Dutta, MD
Monday, Oct 22
10:45 am

MO_15_2834 - Cognitive-Linguistic Deficits Following Treatment of Brain Tumors: Results of a Prospective Pilot Study
Location: Innovation Hub, Exhibit Hall 3
Brianna Tranby, MA
Monday, Oct 22
10:45 am

MO_15_2839 - Similar local control rates for patients with meningiomas treated with proton therapy vs. IMRT
Location: Innovation Hub, Exhibit Hall 3
Kevin Tran, BS
Monday, Oct 22
10:45 am

MO_15_2846 - Safety and Efficacy of Proton Beam Therapy for High-Grade Glioma: Initial Report From the Proton Collaborative Group(PCG)
Location: Innovation Hub, Exhibit Hall 3
Sujay Vora, MD
Monday, Oct 22
10:45 am

MO_15_2847 - Long-term Outcomes and Imaging Response for Image-Guided Stereotactic Radiosurgery (IG-SRS) of Brain Arteriovenous Malformations (AVM)
Location: Innovation Hub, Exhibit Hall 3
Jacob Trotter, BS
Monday, Oct 22
10:45 am

MO_15_2848 - Nodular Leptomeningeal Disease - A Distinct Pattern of Recurrence After Post-Resection Stereotactic Radiosurgery for Brain Metastases: A Multi-Institutional Study of Inter-Observer Reliability
Location: Innovation Hub, Exhibit Hall 3
Brandon Turner, MS
Monday, Oct 22
10:45 am

MO_15_2850 - Assessing the Association between Tumor Location and Toxicity Outcomes after Stereotactic Radiosurgery for Brain Metastases
Location: Innovation Hub, Exhibit Hall 3
Boya Wang, BS
Monday, Oct 22
10:45 am

MO_15_2852 - Radiation Dose Escalation for Localized Ependymoma
Location: Innovation Hub, Exhibit Hall 3
Jennifer Vogel, MD – University of Pennsylvania
Monday, Oct 22
10:45 am

MO_15_2854 - Feasibility of Hippocampal Dose-volume Parameters Associated with Memory Decline in Volumetric Modulated Arc Therapy for Supratentorial Tumors
Location: Innovation Hub, Exhibit Hall 3
Shigeo Takahashi, MD, PhD
Monday, Oct 22
10:45 am

MO_15_2857 - Quantitative MR measurements of mean diffusivity in glioblastoma patients with Tumor Treating Fields plus standard therapy versus standard treatment alone
Location: Innovation Hub, Exhibit Hall 3
Josef Vymazal, MD, DSc
Monday, Oct 22
10:45 am

MO_16_2864 - Safety of TTFields applied to the torso: Meta-analysis of 176 patients from four phase I-II trials
Location: Innovation Hub, Exhibit Hall 3
Ignance Vergote
Monday, Oct 22
10:45 am

MO_16_2868 - Stereotactic Body Radiation Therapy (SBRT) for Spinal Metastases at the Extremes of the Spine: Imaging-Based Outcomes for Cervical and Sacral Metastases
Location: Innovation Hub, Exhibit Hall 3
K. Liang Zeng, MD
Monday, Oct 22
10:45 am

MO_16_2869 - A Pilot/Phase II Study of Stereotactic Radiosurgery for Brain Metastases Using Rational Dose Selection
Location: Innovation Hub, Exhibit Hall 3
James Yu, MD, MHS – Yale University
Monday, Oct 22
10:45 am

MO_16_2875 - Feasibility of a Risk-Adapted Approach to Whole Brain Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Ted Yanagihara, MD, PhD
Monday, Oct 22
10:45 am

MO_16_2878 - Cancer Genetic Markers According to Radiotherapeutic Response in Patients with Glioblastoma - Radiogenomic Approach for Precision Medicine
Location: Innovation Hub, Exhibit Hall 3
Kyungmi Yang, MD
Monday, Oct 22
10:45 am

MO_16_2879 - Treatment of complex brain metastases with helical Tomotherapy: Results of a phase II trial
Location: Innovation Hub, Exhibit Hall 3
Siran Yang, MD
Monday, Oct 22
10:45 am

MO_16_2884 - Stereotactic Radiosurgery as a Component of Treatment for Brain Metastases in Small Cell Lung Cancer Patients
Location: Innovation Hub, Exhibit Hall 3
Justin Yuan, BS
Monday, Oct 22
10:45 am

MO_16_2890 - Outcomes of whole brain radiation with simultaneous in-field boost (SIB) for the treatment of brain metastases
Location: Innovation Hub, Exhibit Hall 3
Jim Zhong, MD
Monday, Oct 22
10:45 am

MO_16_2894 - Propensity-Matched Analysis of Prognosis Following Whole Brain Radiation Therapy Alone Versus Whole Brain Radiation Therapy Combined with Local Boost in Small Cell Lung Cancer Patients With Brain Metastases
Location: Innovation Hub, Exhibit Hall 3
Qingyang Zhuang, BS
Monday, Oct 22
10:45 am

MO_16_2895 - Spine Stereotactic Body Radiation Therapy with Concurrent Systemic Therapies for Treatment of Metastatic Breast Cancer
Location: Innovation Hub, Exhibit Hall 3
Rachel Zhuang, BS
Monday, Oct 22
10:45 am

92 - Elevated MGMT Gene Expression Is Independently Associated With Worse Overall Survival in NRG Oncology/RTOG 9813: A Phase III Study of Radiation Therapy (RT) and Temozolomide (TMZ) Versus RT and Nitrosourea (NU) in Anaplastic Grade III Glioma
Location: Room 004
Jessica Fleming, PhD
Monday, Oct 22
10:45 am

SS 13 - CNS 2 - Gliomas
Location: Room 004
Raju Raval, MD, DPhil
Monday, Oct 22
10:55 am

93 - MGMT Protein Expression Adds Prognostic Value Beyond MGMT Promoter Methylation and Stratifies Survival Prognoses of Un-Methylated Glioblastoma Patients
Location: Room 004
Aline Becker, MD, PhD
Monday, Oct 22
11:05 am

94 - Development and Validation of Xenograft-Based Platform-Independent Gene Signatures That Predict Response to Alkylating Chemotherapy, Radiation, and Combination Therapy in Glioblastoma.
Location: Room 004
Shuang Zhao, MD, MSE
Monday, Oct 22
11:15 am

95 - Analysis of RTOG-RPA Scores in the Phase 3 EF-14 Trial of Tumor Treating Fields With Temozolomide (TTFields/TMZ) Versus TMZ Alone in Newly Diagnosed Glioblastoma.
Location: Room 004
Kevin Choe, MD, PhD
Monday, Oct 22
11:25 am

Scientific Discussant
Location: Room 004
Kevin Camphausen, MD
Monday, Oct 22
11:35 am

96 - A Phase 2 Trial of Neoadjuvant Temozolomide (TMZ) Followed By Accelerated Hypofractionated Radiation Therapy (AHRT) and TMZ Followed By Adjuvant TMZ in Patients with Newly Diagnosed Glioblastoma (GBM): Long Term Survival and Toxicity Analysis
Location: Room 004
George Shenouda, MD, PhD
Monday, Oct 22
11:45 am

97 - A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients With Glioblastoma: Integrative Analyses of Transcriptome and Methylome
Location: Room 004
Bum Sup Jang, MD
Monday, Oct 22
11:55 am

98 - Risk Factors for Progression of Low Grade Glioma Following Gross Total Resection and Observation in the Molecular Era
Location: Room 004
Vamsi Varra, BS
Monday, Oct 22
12:05 pm

Scientific Discussant
Location: Room 004
Ranjit Bindra, MD, PhD – Yale University
Monday, Oct 22
4:15 pm

Presentation 1
Location: Room 303
Kristin Redmond, MD, MPH – Johns Hopkins University
Monday, Oct 22
4:15 pm

eContouring for CNS/SBRT Spine

Location: Room 303
Stephanie Terezakis, MD – Johns Hopkins School of Medicine
Monday, Oct 22
4:15 pm

eContouring for CNS/SBRT Spine

Location: Room 303
Karyn Goodman, MD, MS – University of Colorado Cancer Center
Monday, Oct 22
4:15 pm

eContouring 08 (Live SA-CME) - eContouring for CNS/SBRT Spine

Location: Room 303
Monday, Oct 22
4:35 pm

Presentation 2
Location: Room 303
Simon Lo, MB, ChB, FACR, FASTRO – University of Washington
Tuesday, Oct 23
1:00 pm

Case: Surgical Management of Gliomas
Location: Room 008
Albert Kim, MD, PhD
Tuesday, Oct 23
1:00 pm

EDU 24 - (INTERACTIVE) Challenging Cases in the Management of Gliomas
Location: Room 008
Christina Irene Tsien, MD – Washington University, St. Louis
Tuesday, Oct 23
1:20 pm

Update on Brain Tumor Imaging in the Molecular Era
Location: Room 008
Soonmee Cha, MD
Tuesday, Oct 23
1:40 pm

Case: Management of Primary and Recurrent GBM
Location: Room 008
Roger Stupp, MD
Tuesday, Oct 23
2:00 pm

Case: Management of Low Grade and Anaplastic Gliomas
Location: Room 008
Christina Irene Tsien, MD – Washington University, St. Louis
Tuesday, Oct 23
2:20 pm

Audience Q&A
Location: Room 008
Christina Irene Tsien, MD – Washington University, St. Louis
Tuesday, Oct 23
4:45 pm

Indications and contraindications for single and fractionated SRS for benign brain tumors
Location: Room 007 C/D
Joshua Silverman, MD, PhD – New York University Cancer Center
Tuesday, Oct 23
4:45 pm

Panel 13 - (INTERACTIVE) Practical Case Based Discussions of Single vs Fractionated Stereotactic Radiosurgery for Benign Brain Tumors
Location: Room 007 C/D
Tony Wang, MD – Columbia University Medical Center
Tuesday, Oct 23
5:05 pm

Surgical management of benign brain tumors in the era of molecular classification
Location: Room 007 C/D
Albert Kim, MD, PhD
Tuesday, Oct 23
5:25 pm

Advances in neuroimaging for benign brain tumors
Location: Room 007 C/D
Jason Johnson, MD
Tuesday, Oct 23
5:45 pm

Contouring and treatment planning - dos and dont's
Location: Room 007 C/D
Tony Wang, MD – Columbia University Medical Center
Tuesday, Oct 23
6:05 pm

Audience Q&A
Location: Room 007 C/D
Tony Wang, MD – Columbia University Medical Center
Wednesday, Oct 24
7:45 am

Introduction to spine SBRT including evaluating candidacy and target/normal tissue delineation
Location: Room 303
Kristin Redmond, MD, MPH – Johns Hopkins University
Wednesday, Oct 24
7:45 am

EDU 33 - (INTERACTIVE) Stereotactic Body Radiation Therapy for Spine Metastases: What Can Be Offered When Conventional Radiation Fails?
Location: Room 303
Kristin Redmond, MD, MPH – Johns Hopkins University
Wednesday, Oct 24
8:03 am

Local control and toxicity of spine SBRT
Location: Room 303
Scott Soltys, MD – Stanford Department of Radiation Oncology
Wednesday, Oct 24
8:21 am

Re-irradiation of spinal metastases with a focus on normal tissue tolerance in the re-irradiation setting
Location: Room 303
Amol Ghia, MD
Wednesday, Oct 24
8:39 am

Management options when radiation therapy fails
Location: Room 303
Mark Bilsky, MD
Wednesday, Oct 24
8:57 am

Audience Q&A
Location: Room 303
Kristin Redmond, MD, MPH – Johns Hopkins University
Wednesday, Oct 24
1:30 pm

289 - Treatment of Brain Metastases With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors: An International Meta-Analysis of Individual Patient Data
Location: Room 004
Eric Lehrer, MD, MS
Wednesday, Oct 24
1:30 pm

SS 40 - CNS 3 - CNS Metastasis
Location: Room 004
Stuart Burri, MD; Kevin Chua, MBBS
Wednesday, Oct 24
1:40 pm

290 - Improved Survival Following Immunotherapy in Patients With Lung and Melanoma Primaries Metastatic to the Brain Treated With Upfront Stereotactic Radiosurgery
Location: Room 004
Claire Lanier, BS
Wednesday, Oct 24
1:50 pm

291 - Preoperative Radiosurgery For Resected Brain Metastases: Updated Analysis of Efficacy and Toxicity Of A Novel Treatment Paradigm
Location: Room 004
Roshan Prabhu, MD, MS
Wednesday, Oct 24
2:00 pm

292 - Initial SRS for Patients With 5-15 Brain Metastases: Results of a Multi-Institutional Experience
Location: Room 004
Ryan Hughes, MD – Wake Forest Baptist Medical Center
Wednesday, Oct 24
2:10 pm

293 - A Phase II Study of Post-Operative Stereotactic Body Radiation Therapy (SBRT) for Solid Tumor Spine Metastases
Location: Room 004
Kristin Redmond, MD, MPH – Johns Hopkins University
Wednesday, Oct 24
2:20 pm

294 - Patterns of Failure and Outcomes Based On Management of Leptomeningeal Disease After Surgical Resection and Radiosurgery for Brain Metastases: A Multi-Institutional Analysis
Location: Room 004
Roshan Prabhu, MD, MS
Wednesday, Oct 24
2:30 pm

295 - Randomized Phase III Trial Comparing Gamma Knife and Linac Based (EDGE) Approaches for Brain Metastases Radiosurgery: Results from the Gadget Trial
Location: Room 004
Pierina Navarria, MD
Wednesday, Oct 24
2:40 pm

296 - Salvage Stereotactic Radiosurgery is Associated With Improved Overall Survival Compared to Whole Brain Radiation in the Setting of Progressive Brain Metastases
Location: Room 004
Michael Soike, MD – Wake Forest University Medical Center
Wednesday, Oct 24
2:50 pm

Scientific Discussant
Location: Room 004
Ayal Aizer, MD
Wednesday, Oct 24
3:15 pm

Radiosurgery versus Neurosurgery (or both?): the evidence
Location: Room 006
Stephanie Weiss, MD, FASTRO – Fox Chase Cancer Center
Wednesday, Oct 24
3:15 pm

Panel 23 (Live SA-CME) - An Evidence-Driven Guide to Thinking Through Radiation and Surgery for Brain Metastasis
Location: Room 006
Lawrence Kleinberg, MD; Stephen Shiao, MD, PhD
Wednesday, Oct 24
3:35 pm

Post operative SRS
Location: Room 006
Kathryn Beal, MD – Memorial Sloan Kettering Cancer Center
Wednesday, Oct 24
3:55 pm

Technique for post-operative treatment planning
Location: Room 006
Scott Soltys, MD – Stanford Department of Radiation Oncology
Wednesday, Oct 24
4:15 pm

Preoperative Radiosurgery
Location: Room 006
Erin Murphy, MD
Sunday, Oct 21
9:45 am

Updates In The Management of Brain Metastases
Location: Room 304
Simon Lo, MB, ChB, FACR, FASTRO – University of Washington
Sunday, Oct 21
9:45 am

PRO 07 - PRO - Central Nervous System
Location: Room 304
Christina Irene Tsien, MD – Washington University, St. Louis
Sunday, Oct 21
10:05 am

Recent Advances In The Evaluation and Management Of Gliomas (both low grade and high grade)
Location: Room 304
Christina Irene Tsien, MD – Washington University, St. Louis
Sunday, Oct 21
10:45 am

Meet the Expert - Central Nervous System
Location: ASTRO Connect: CNS #2245
Yoshiya Yamada, MD, FRCPC – Memorial Sloan Kettering Cancer Center
Sunday, Oct 21
10:45 am

MTE 13 - Meet The Expert Yoshiya Yamada, MD, FRCPC - CNS - Sunday
Sunday, Oct 21
1:45 pm

Meet the Expert - Central Nervous System
Location: ASTRO Connect: CNS #2245
Joshua Silverman, MD, PhD – New York University Cancer Center
Sunday, Oct 21
1:45 pm

MTE 18 - Meet The Expert Joshua S. Silverman, MD, PhD - CNS - Sunday
Sunday, Oct 21
4:15 pm

Meet the Expert - Central Nervous System
Location: ASTRO Connect: CNS #2245
Eric Chang, MD, FASTRO – Keck School of Medicine of USC
Sunday, Oct 21
4:15 pm

MTE 23 - Meet The Expert Eric Chang, MD, FASTRO - CNS - Sunday
Monday, Oct 22
11:15 am

Meet the Expert - Central Nervous System
Location: ASTRO Connect: CNS #2245
Stephanie Weiss, MD, FASTRO – Fox Chase Cancer Center
Monday, Oct 22
11:15 am

MTE 28 - Meet The Expert Stephanie Weiss, MD, FASTRO - CNS - Monday
Monday, Oct 22
4:15 pm

Meet the Expert - Central Nervous System
Location: ASTRO Connect: CNS #2245
Lia Halasz, MD – University of Washington
Monday, Oct 22
4:15 pm

MTE 33 - Meet The Expert Lia M. Halasz, MD - CNS - Monday
Tuesday, Oct 23
10:45 am

Meet the Expert - Central Nervous System
Location: ASTRO Connect: CNS #2245
Vinai Gondi, MD – Northwestern Medicine Cancer Center Warrenville
Tuesday, Oct 23
10:45 am

MTE 38 - Meet The Experts Vinai Gondi, MD and Minesh Mehta, MD, ChB, FASTRO - CNS - Tuesday
Tuesday, Oct 23
1:30 pm

Meet the Expert - Central Nervous System
Location: ASTRO Connect: CNS #2245
Tony Wang, MD – Columbia University Medical Center
Tuesday, Oct 23
1:30 pm

MTE 43 - Meet The Expert Tony Wang, MD - CNS - Tuesday
Tuesday, Oct 23
3:15 pm

Meet the Expert - Central Nervous System
Location: ASTRO Connect: CNS #2245
Kristin Redmond, MD, MPH – Johns Hopkins University
Tuesday, Oct 23
3:15 pm

MTE 48 - Meet The Expert Kristin Redmond, MD, MPH - CNS - Tuesday
Tuesday, Oct 23
4:15 pm

Meet the Expert - Central Nervous System
Location: ASTRO Connect: CNS #2245
Christina Irene Tsien, MD – Washington University, St. Louis
Tuesday, Oct 23
4:15 pm

MTE 53 - Meet The Expert Christina Irene Tsien, MD - CNS - Tuesday
Gastrointestinal Cancer
Sunday, Oct 21
10:30 am

eContouring for Prostate Cancer

Location: Room 303
Manisha Palta, MD – Duke Cancer Institute
Sunday, Oct 21
10:30 am

eContouring for Gastrointestinal Cancer

Location: Room 303
Stephanie Terezakis, MD – Johns Hopkins School of Medicine
Sunday, Oct 21
10:30 am

eContouring for Gastrointestinal Cancer

Location: Room 303
Karyn Goodman, MD, MS – University of Colorado Cancer Center
Sunday, Oct 21
10:30 am

eContouring 04 - eContouring for Gastrointestinal Cancer

Location: Room 303
Sunday, Oct 21
10:50 am

eContouring for Prostate Cancer

Location: Room 303
Salma Jabbour, MD – Rutgers Cancer Institute of New Jersey
Sunday, Oct 21
1:15 pm

Global overview of HyTEC
Location: Room 301
Lawrence Marks, MD, FASTRO
Sunday, Oct 21
1:15 pm

Panel 01 - (INTERACTIVE) HyTEC Report: SBRT/SABR in Abdominal Regions
Location: Room 301
Jimm Grimm, PhD; Ellen Yorke, PhD, FASTRO
Sunday, Oct 21
1:32 pm

Normal tissue dose-volume effects for SBRT-induced liver and gastrointestinal toxicities
Location: Room 301
Moyed Miften, PhD
Sunday, Oct 21
1:49 pm

Tumor control of primary and metastatic liver malignancies with SBRT
Location: Room 301
Nitin Ohri, MD, MS – Albert Einstein College of Medicine
Sunday, Oct 21
2:06 pm

SBRT and multidisciplinary advances for pancreatic cancer
Location: Room 301
Joseph Herman, MD, MS – MD Anderson Cancer Center
Sunday, Oct 21
2:30 pm

Concluding remarks on HyTEC dose-response modeling and reporting standards
Location: Room 301
Andrew Jackson, PhD
Sunday, Oct 21
2:40 pm

Audience Q&A
Location: Room 301
Jimm Grimm, PhD
Sunday, Oct 21
1:15 pm

SU_1_2000 - Correlation Between Immune Status After Neoadjuvant Therapy and Complete Response Rate in Patients with Locally Advanced Rectal Adenocarcinoma
Location: Innovation Hub, Exhibit Hall 3
Namita Agrawal, MD, BS
Sunday, Oct 21
1:15 pm

SU_1_2001 - Delta Radiomics Analysis for Hybrid MR-RT Imaging in Rectal Cancer for Response Prediction: A Hypothesis Generating Study
Location: Innovation Hub, Exhibit Hall 3
Nicola Dinapoli, MD, PhD
Sunday, Oct 21
1:15 pm

SU_1_2002 - Three-Dimensional Printing of Adaptive Bolus for Squamous Cell Carcinoma of the Anus
Location: Innovation Hub, Exhibit Hall 3
Michael Cardenas, MD
Sunday, Oct 21
1:15 pm

SU_1_2003 - Prospective Clinical Study of Capecitabine plus Oxaliplatin Concurrent Chemoradiotherapy after Radical Resection of Rectal Cancer
Location: Innovation Hub, Exhibit Hall 3
Wang Chen
Sunday, Oct 21
1:15 pm

SU_1_2004 - Stereotactic Body Radiation Therapy for Metastatic Colorectal Cancer: Comprehensive Review from a Large Academic Institution
Location: Innovation Hub, Exhibit Hall 3
Robert Thompson, MD
Sunday, Oct 21
1:15 pm

SU_1_2005 - Importance of Tumor Regression Grade in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy
Location: Innovation Hub, Exhibit Hall 3
Changhoon Song, MD, PhD
Sunday, Oct 21
1:15 pm

SU_1_2006 - Clinical Outcomes of Rectal Squamous Cell Carcinomas Treated With Chemoradiotherapy With or Without Surgery: A Rare Cancer Network Study.
Location: Innovation Hub, Exhibit Hall 3
Berardino De Bari
Sunday, Oct 21
1:15 pm

SU_1_2007 - Prognostic implications of altering the nodal staging for anal cancer in the American Joint Committee on Cancer 8^th(AJCC8) Edition Staging Manual
Location: Innovation Hub, Exhibit Hall 3
Joshua Elson, MD, MPH
Sunday, Oct 21
1:15 pm

SU_1_2008 - The Utility of Positron Emission Tomography (PET) To Guide Radiation Therapy Target Volume Determination As Compared With Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) for Rectal Cancer
Location: Innovation Hub, Exhibit Hall 3
Robert Fain, MD
Sunday, Oct 21
1:15 pm

SU_1_2009 - Overcoming the Barriers to the Use of Short Course Radiation Therapy in Locally Advanced Rectal Cancer: A Phase 1 Study of Short Course Radiation Therapy Concurrent with 5-Fluorouracil
Location: Innovation Hub, Exhibit Hall 3
Emma Fields, MD – Virginia Commonwealth University
Sunday, Oct 21
1:15 pm

SU_2_2010 - Immune Inflammation Indicators Predict Outcome in Anal Cancer Patients Undergoing Concurrent Chemo-radiation
Location: Innovation Hub, Exhibit Hall 3
Pierfrancesco Franco, MD, PhD
Sunday, Oct 21
1:15 pm

SU_2_2011 - Patterns of Inguinal Lymph Node Metastases in Anal Cancer: Recommendations for Elective Clinical Target Volume (CTV) Delineation
Location: Innovation Hub, Exhibit Hall 3
Allison Garda, MD
Sunday, Oct 21
1:15 pm

SU_2_2012 - Long-Term Survival and Local Control Outcomes in Oligometastatic Colorectal Cancer Treated with Liver Stereotactic Body Radiation Therapy Long-Term Survival and Local Control Outcomes in Oligometastatic Colorectal Cancer
Location: Innovation Hub, Exhibit Hall 3
Jason Hinton, MD, PharmD
Sunday, Oct 21
1:15 pm

SU_2_2013 - Intensity-modulated proton therapy (IMPT) reduces dose to pelvic bone marrow and normal pelvic organs when compared to volumetric-modulated arc therapy (VMAT) for patients with anal cancer
Location: Innovation Hub, Exhibit Hall 3
Emma Holliday
Sunday, Oct 21
1:15 pm

SU_2_2014 - The Efficacy and Tolerability of S-1 in the Treatment of Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer.
Location: Innovation Hub, Exhibit Hall 3
Nobuki Imano, MD
Sunday, Oct 21
1:15 pm

SU_2_2015 - Metastasis-Directed Stereotactic Body Radiation Therapy for Oligometastatic Colorectal Cancer: a Single Institution Experience
Location: Innovation Hub, Exhibit Hall 3
Krishan Jethwa, MD – Mayo Clinic
Sunday, Oct 21
1:15 pm

SU_2_2017 - Patterns of Care and Comparison of Outcomes Between Primary Anal Squamous Cell Carcinoma and Anal Adenocarcinoma
Location: Innovation Hub, Exhibit Hall 3
Ami Kavi, MD
Sunday, Oct 21
1:15 pm

SU_2_2018 - The Impact of Hemoglobin on Outcomes in Anal Canal Cancer Treated with Definitive Chemoradiation
Location: Innovation Hub, Exhibit Hall 3
Sara Kelm, BS
Sunday, Oct 21
1:15 pm

SU_2_2019 - Short-course hyperfractionated accelerated radiation therapy (SC-HART) for rectal cancer stage UICC II - III (8^th edition). Results from a single Austrian Institution
Location: Innovation Hub, Exhibit Hall 3
Lukas Kocik, MD
Sunday, Oct 21
1:15 pm

SU_2_2020 - Radical Therapeutic Strategies for Primary Unresectable Rectal Cancer- Radiochemotherapy, Conventional Radiation Therapy, and Hyperfractionated Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Malgorzata Kraszkiewicz, MD
Sunday, Oct 21
1:15 pm

SU_3_2021 - Nuclear Export Inhibition for Radiosensitization; a Proof-Of-Concept Phase I Clinical Trial of Neoadjuvant KPT-330 (Selinexor) Plus Chemoradiation in Locally Advanced Rectal Cancer
Location: Innovation Hub, Exhibit Hall 3
Yaacov Lawrence, MD, MRCP
Sunday, Oct 21
1:15 pm

SU_3_2022 - Survival Outcomes and Patterns of Management for Anal Adenocarcinoma: An Analysis of the National Cancer Data Base
Location: Innovation Hub, Exhibit Hall 3
Gary Lewis, MD
Sunday, Oct 21
1:15 pm

SU_3_2023 - Multiple Primary Malignancies in Patients with Anal Squamous Cell Carcinoma
Location: Innovation Hub, Exhibit Hall 3
Diana Li, BA
Sunday, Oct 21
1:15 pm

SU_3_2024 - Nationwide Management and Survival Outcomes of Adenocarcinoma of the Anal Canal
Location: Innovation Hub, Exhibit Hall 3
Richard Li, MD
Sunday, Oct 21
1:15 pm

SU_3_2025 - Safety and Efficacy of Bevacizumab plus Concurrent Chemoradiotherapy for Recurrent or Metastatic Colorectal Cancer
Location: Innovation Hub, Exhibit Hall 3
Yongheng Li, MD, RT, BS
Sunday, Oct 21
1:15 pm

SU_3_2026 - 53BP1 Deletion Induced Treatment Resistance in Neoadjuvant Chemoradiotherapy Rectal Patients By Inhibiting Immune Function
Location: Innovation Hub, Exhibit Hall 3
Hong Ma
Sunday, Oct 21
1:15 pm

SU_3_2027 - Effect of Radiation Therapy Duration on Overall Survival in Anal Squamous Cell Carcinoma: A National Analysis
Location: Innovation Hub, Exhibit Hall 3
Shahil Mehta, BS
Sunday, Oct 21
1:15 pm

SU_3_2028 - The Immune Milieu of Anal Squamous Cell Carcinoma: IDO Expression is Correlated With Poor Outcome
Location: Innovation Hub, Exhibit Hall 3
Devarati Mitra, MD, PhD
Sunday, Oct 21
1:15 pm

SU_3_2029 - Organ Motion During Neoadjuvant Chemoradiotherapy for Rectal Cancer - A Call to Update the RTOG Contouring Guidelines.
Location: Innovation Hub, Exhibit Hall 3
Nataliya Moldovan, MD
Sunday, Oct 21
1:15 pm

SU_3_2030 - Patterns of Care and Outcomes for Early Stage (cT1-T2N0M0) Squamous Cell Carcinoma of the Anus
Location: Innovation Hub, Exhibit Hall 3
Virginia Osborn, MD
Sunday, Oct 21
1:15 pm

SU_4_2032 - Small Cell Carcinoma of the Anus, A Patterns of Care Study Utilizing a Large Hospital-Based Database
Location: Innovation Hub, Exhibit Hall 3
Virginia Osborn, MD
Sunday, Oct 21
1:15 pm

SU_4_2033 - Defining Bowel and Nonsigmoid Bowel Dose Volume Constraints for Pelvic Radiation Therapy in GI Malignancies.
Location: Innovation Hub, Exhibit Hall 3
Sophie Otter, MBBChir
Sunday, Oct 21
1:15 pm

SU_4_2034 - Feasibility Of Wait And Watch Approach After Neoadjuvant Chemoradiotherapy In Rectal Cancer In Low-And Middle- Income Countries : Initial Experience In Tertiary Cancer Centre In India
Location: Innovation Hub, Exhibit Hall 3
Mangesh Patil, MD
Sunday, Oct 21
1:15 pm

SU_4_2035 - HIV-Positive Anal Cancer Patients Treated with Definitive Chemoradiation: Factors Impacting Clinical Outcomes
Location: Innovation Hub, Exhibit Hall 3
Neil Pfister, MD, PhD
Sunday, Oct 21
1:15 pm

SU_4_2037 - An Analysis of Primary Site Radiation, Surgery, and Survival in Metastatic Rectal Cancer: A National Cancer Database Population Study
Location: Innovation Hub, Exhibit Hall 3
Kristofer Roberts, MD – Mayo Clinic
Sunday, Oct 21
1:15 pm

SU_4_2038 - Changes in Pelvic Active Bone Marrow seen on FDG-PET in Patients Receiving Concurrent Chemoradiation for Anal Cancer
Location: Innovation Hub, Exhibit Hall 3
Maxwell Robinson, MS, BS, MSc
Sunday, Oct 21
1:15 pm

SU_4_2039 - Impact of immune status on disease recurrence in HIV+ positive patients diagnosed with anal dysplasia
Location: Innovation Hub, Exhibit Hall 3
Danushka Seneviratne, MD, PhD
Sunday, Oct 21
1:15 pm

SU_4_2040 - Radiation Therapy Dose in Anal Cancer: Patterns of Care and Survival
Location: Innovation Hub, Exhibit Hall 3
Kimberley Mak, MD, MPH
Sunday, Oct 21
1:15 pm

SU_4_2135 - Outcomes following Stereotactic Body Radiation Therapy for Patients with Child-Pugh B or C Hepatocellular Carcinoma
Location: Innovation Hub, Exhibit Hall 3
Aditya Juloori, MD – Cleveland Clinic Foundation
Sunday, Oct 21
1:15 pm

SU_5_2041 - MRI radiomics signature as a potential biomarker to predict different KRAS status in colorectal cancer patients and tumor cells
Location: Innovation Hub, Exhibit Hall 3
Lijun Shen, MD
Sunday, Oct 21
1:15 pm

SU_5_2042 - Time to surgery after neoadjuvant chemoradiation for rectal carcinoma is an independent predictor of total mesorectal excision quality
Location: Innovation Hub, Exhibit Hall 3
Igor Sirak, MD, PhD
Sunday, Oct 21
1:15 pm

SU_5_2043 - Location-Specific Skin Dosimetry Is Associated With Treatment Breaks and Duration In Concurrent Chemoradiotherapy For Anal Cancer
Location: Innovation Hub, Exhibit Hall 3
Matthew Susko, MD, MS
Sunday, Oct 21
1:15 pm

SU_5_2044 - Evaluation of Patient Characteristics, Treatment Decisions and Survival of Young Patients Under The Age of 50 Diagnosed With Colorectal Carcinoma.
Location: Innovation Hub, Exhibit Hall 3
Marcher Thompson, MD
Sunday, Oct 21
1:15 pm

SU_5_2045 - FAK alleviates radiation-induced rectal injury through AKT Signaling Pathway
Location: Innovation Hub, Exhibit Hall 3
Wenzhi Tu, PhD
Sunday, Oct 21
1:15 pm

SU_5_2046 - Outcomes Prediction in Pre-Operative Radiation Therapy Locally Advanced Rectal Cancer: Leucocyte Assessment As Immune Biomarker
Location: Innovation Hub, Exhibit Hall 3
Alexis Vallard, MD
Sunday, Oct 21
1:15 pm

SU_5_2047 - Poor Prognostic and Staging Value of Tumor Deposits in Locally Advanced Rectal Cancer With Neoadjuvant Chemoradiotherapy
Location: Innovation Hub, Exhibit Hall 3
Yaqi Wang, MD
Sunday, Oct 21
1:15 pm

SU_5_2048 - Clinical Study of Bone Marrow-Sparing Neoadjuvant Chemoradiotherapy for Rectal Cancer
Location: Innovation Hub, Exhibit Hall 3
Yijun Wang, MS
Sunday, Oct 21
1:15 pm

SU_5_2049 - Definitive Pelvic Radiation Therapy and Survival of Patients With Newly Diagnosed Metastatic Anal Cancer
Location: Innovation Hub, Exhibit Hall 3
Yuefeng Wang, MD, PhD
Sunday, Oct 21
1:15 pm

SU_5_2051 - Definitive Radiation Therapy With Chemotherapy for Stage IV Anal Cancer: A National Cancer Database Analysis
Location: Innovation Hub, Exhibit Hall 3
Tyler Wilhite, MD – Mayo Clinic
Sunday, Oct 21
1:15 pm

SU_5_2052 - An analysis of toxicity and outcomes in older versus younger rectal cancer patients treated with trimodality therapy
Location: Innovation Hub, Exhibit Hall 3
Jessica Wong, MD
Sunday, Oct 21
1:15 pm

SU_6_2050 - Intensity-Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy in Rectal Cancer Treated with Neoadjuvant Concurrent Chemoradiation: A Meta-Analysis and Pooled-Analysis of Acute Toxicity
Location: Innovation Hub, Exhibit Hall 3
Chan Woo Wee, MD
Sunday, Oct 21
1:15 pm

SU_6_2053 - Sarcopenia is associated with inferior response to neoadjuvant chemoradiation in patients with locally advanced rectal cancer
Location: Innovation Hub, Exhibit Hall 3
Jeng-You WU, MD
Sunday, Oct 21
1:15 pm

SU_6_2054 - The High Expression of Inhibitory Lymphoid Receptors After Preoperative Radiation Therapy Predicts Favorable Prognosis of Locally Advanced Rectal Cancer
Location: Innovation Hub, Exhibit Hall 3
Junxin Wu, MD
Sunday, Oct 21
1:15 pm

SU_6_2055 - Dosimetric Predictors of Acute Hematologic Toxicity Due to Intensity-Modulated Pelvic Radiation Therapy With Concurrent Chemotherapy for Chinese Rectal and Cervical Cancer Patients
Location: Innovation Hub, Exhibit Hall 3
Yongqiang Yang, MD
Sunday, Oct 21
1:15 pm

SU_6_2056 - Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Locally Advanced Rectal Cancer Patients Treated with Concurrent Weekly Irinotecan in Combination with Capecitabine-Based Chemoradiotherapy and Neoadjuvant IMRT
Location: Innovation Hub, Exhibit Hall 3
Jing Zhang
Sunday, Oct 21
1:15 pm

SU_6_2057 - Assessing Radiation Induced Liver Damage Following MR-Guided Stereotactic Body Radiation Therapy (SBRT): Challenging Current Dose Constraints
Location: Innovation Hub, Exhibit Hall 3
Aleksandra Kuczmarska-Haas, MD
Sunday, Oct 21
1:15 pm

SU_6_2058 - Differing Radiation Doses Associated with Improved Overall Survival in Trimodality Versus Bimodality Treatment for Esophageal Cancer
Location: Innovation Hub, Exhibit Hall 3
Christopher Anker, MD
Sunday, Oct 21
1:15 pm

SU_6_2059 - Acute Toxicities and Short-Term Follow-up of Patients Treated with Pencil-Beam Scanning Proton Beam Radiation Therapy for Esophageal Carcinoma: A Single-Center Experience
Location: Innovation Hub, Exhibit Hall 3
Ronik Bhangoo, MD
Sunday, Oct 21
1:15 pm

SU_6_2060 - Modeling Variability for at Risk Lung Functionality By Location of Esophageal Cancer Radiation Therapy Fields
Location: Innovation Hub, Exhibit Hall 3
Yiqing Butler-Xu, MD
Sunday, Oct 21
1:15 pm

SU_6_2061 - Pilot Study of Potential Activation of c-MYC by Aurora Kinase A in Everolimus-Resistant Localized Esophageal Cancer Treated with XELOX followed by Carboplatin/Radiation
Location: Innovation Hub, Exhibit Hall 3
A. Bapsi Chakravarthy, MD, FASTRO
Sunday, Oct 21
1:15 pm

SU_6_2062 - Concurrent Chemoradiotherapy (CCRT) for Stage I-II Esophageal Cancer Patients
Location: Innovation Hub, Exhibit Hall 3
Junichi Fukada, MD, PhD
Sunday, Oct 21
1:15 pm

SU_7_2063 - Nomogram to predict disease-free survival in stage IB-III thoracic esophageal squamous cell carcinoma patients after radical esophagectomy
Location: Innovation Hub, Exhibit Hall 3
Wei Deng, MD – National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences
Sunday, Oct 21
1:15 pm

SU_7_2064 - Can Mean Pericardial Irradiated Dose (MPD) Predict Pericardial Effusion After Chemoradiotherapy in Esophageal Cancer Patients? ?Normal Tissue Complication Probability (NTCP) Model Based Analyses
Location: Innovation Hub, Exhibit Hall 3
Junichi Fukada, MD, PhD
Sunday, Oct 21
1:15 pm

SU_7_2065 - A Multi-institutional Analysis of Dosimetric Predictors of Toxicity Following Trimodality Therapy for Esophageal Cancer
Location: Innovation Hub, Exhibit Hall 3
Aurelie Garant, MD
Sunday, Oct 21
1:15 pm

SU_7_2066 - A Prospective Pilot Study of Pencil Beam Scanning (PBS) Proton Radiation Therapy (RT) as a Component of Trimodality Therapy for Esophageal Cancer
Location: Innovation Hub, Exhibit Hall 3
Christopher Hallemeier, MD
Sunday, Oct 21
1:15 pm

SU_7_2067 - Effect of Patient Companionship on Patients With Esophageal Cancer Undergoing Definitive Chemoradiotherapy
Location: Innovation Hub, Exhibit Hall 3
Joseph Ho, MD
Sunday, Oct 21
1:15 pm

SU_7_2068 - Radiobiological Determination of ¹⁸F-FDG PET/CT guiding Dose Escalation in Esophageal Cancer
Location: Innovation Hub, Exhibit Hall 3
Man Hu
Sunday, Oct 21
1:15 pm

SU_7_2069 - Propensity Score-Matched Analysis to Evaluate the Impact of Re-irradiation on Long-term Prognosis for Recurrent Esophageal Cancer
Location: Innovation Hub, Exhibit Hall 3
Yunxia Huang, BS
Sunday, Oct 21
1:15 pm

SU_7_2070 - Long-Term Follow-Up Results of Concurrent Chemo-Proton Therapy for Esophageal Cancer
Location: Innovation Hub, Exhibit Hall 3
Hitoshi Ishikawa, MD, PhD
Sunday, Oct 21
1:15 pm

SU_7_2071 - Combination of radiation therapy and anti-PD-1 antibody SHR-1210 in treating patients with esophageal squamous cell cancer
Location: Innovation Hub, Exhibit Hall 3
Zhao Jing
Sunday, Oct 21
1:15 pm

SU_7_2072 - Early Prediction of Response to Radiation Therapy Using Inter-Fractional 18F-FDG PET/CT in Esophageal Cancer
Location: Innovation Hub, Exhibit Hall 3
Nalee Kim, MD
Sunday, Oct 21
1:15 pm

SU_8_2073 - Clinical Characteristics and Prognosis of Thoracicesophageal Squamous Cell Carcinoma with Abdominal Lymph Node Metastasis
Location: Innovation Hub, Exhibit Hall 3
Jiancheng Li, MD
Sunday, Oct 21
1:15 pm

SU_8_2074 - Adherence and Reasons for Non-Adherence to a Tri-Modality Regimen in the Treatment of Esophageal Cancer
Location: Innovation Hub, Exhibit Hall 3
Daniel Koffler
Sunday, Oct 21
1:15 pm

SU_8_2075 - Exploration of Radiosensitivity-related LncRNAs in Esophageal Cancer Stem Cell
Location: Innovation Hub, Exhibit Hall 3
Jiancheng Li, MD
Sunday, Oct 21
1:15 pm

SU_8_2076 - Patient-Reported Outcome Measures during Chemoradiotherapy for Esophageal Cancer and Relationship with Pathologic Response
Location: Innovation Hub, Exhibit Hall 3
Puyao Li, MD
Sunday, Oct 21
1:15 pm

SU_8_2077 - Efficacy and Safety of Apatinib With or Without Radiation Therapy as Second-Line or Beyond Therapy in Patients with Advanced/Recurrent Esophageal Squamous Cell Carcinoma
Location: Innovation Hub, Exhibit Hall 3
Tao Li, MD, PhD
Sunday, Oct 21
1:15 pm

SU_8_2078 - Impact of Chemoradiotherapy Intensity on Pathological Complete Response In Patients With Esophageal Cancer Receiving Trimodality Therapy
Location: Innovation Hub, Exhibit Hall 3
Jhenbin Lin, MD
Sunday, Oct 21
1:15 pm

SU_8_2079 - PD-L1 Expression and the Effect With Radiosensitivity and Prognosis in Esophageal Squamous Cell Carcinom
Location: Innovation Hub, Exhibit Hall 3
Dai Yuan Ma, MD
Sunday, Oct 21
1:15 pm

SU_8_2080 - Lung V20 As a Prognostic Factor of Survival In Patients With Esophageal Cancer Who Received Neoadjuvant Chemoradiotherapy
Location: Innovation Hub, Exhibit Hall 3
Jhenbin Lin, MD
Sunday, Oct 21
1:15 pm

SU_8_2081 - A Reliable Nomogram is identified to predict the overall survival for patients with esophageal squamous cancer after chemoradiation therapy followed by surgery
Location: Innovation Hub, Exhibit Hall 3
Mingwei Ma, MD
Sunday, Oct 21
1:15 pm

SU_8_2082 - Pathologic Tumor Response to Neoadjuvant Chemoradiation Predicts Survival in Esophageal Cancer
Location: Innovation Hub, Exhibit Hall 3
Alexander Moeller, BS
Sunday, Oct 21
1:15 pm

SU_9_2083 - Brachytherapy in the Management of Esophageal Cancer: A Single Institution Experience
Location: Innovation Hub, Exhibit Hall 3
Nikitha Moideen, MD
Sunday, Oct 21
1:15 pm

SU_9_2084 - Possibility of conversion surgery and histological evaluation in definite cT4 patients of esophageal cancer treated with preoperative chemoradiation followed by surgery
Location: Innovation Hub, Exhibit Hall 3
Miyako Myojin, MD, PhD
Sunday, Oct 21
1:15 pm

SU_9_2085 - The Value of Postoperative Radiation Therapy for 1 to 2 Pathological Lymph Nodes Metastases of Esophageal Squamous Cell Carcinoma Using Propensity Score-Matched: Analysis from Two-Center Study
Location: Innovation Hub, Exhibit Hall 3
Wenjie Ni, MD
Sunday, Oct 21
1:15 pm

SU_9_2086 - Dose Dependent Association of Vertebral Body irradiation and Lymphopenia During Chemoradiation for Esophageal Cancer
Location: Innovation Hub, Exhibit Hall 3
Neil Newman, MD, MS
Sunday, Oct 21
1:15 pm

SU_9_2087 - Effect of Adjuvant Radiation Therapy on Survival in Resected Thoracic Esophageal Squamous Cell Carcinoma According to the 8^th AJCC Stage System: Pooled Analysis of Two Cancer Center in China
Location: Innovation Hub, Exhibit Hall 3
Wenjie Ni, MD
Sunday, Oct 21
1:15 pm

SU_9_2088 - Salvage Radiation Therapy with Elective Nodal Irradiation for Superficial Esophageal Cancer after Incomplete Endoscopic Resection
Location: Innovation Hub, Exhibit Hall 3
Ikuno Nishibuchi, MD, PhD
Sunday, Oct 21
1:15 pm

SU_9_2089 - Safety and Effect of Radiation Therapy Combined with Anti-PD-1 Antibody SHR-1210 As First-Line Treatment on Patients with Intolerable Concurrent Chemoradiotherapy Esophageal Cancer: A Phase 1B Clinical Trial
Location: Innovation Hub, Exhibit Hall 3
Qingsong Pang, MD
Sunday, Oct 21
1:15 pm

SU_9_2090 - Hematologic Toxicity of Single Posterior Pencil-Beam Scanning Approach for Esophageal Cancer
Location: Innovation Hub, Exhibit Hall 3
Amber Post, MD, PhD
Sunday, Oct 21
1:15 pm

SU_9_2092 - Early Response to Chemoradiotherapy By Interim 18F-FDG PET/CT Is Associated With Better Survival in Locally Advanced Esophageal Cancer
Location: Innovation Hub, Exhibit Hall 3
Laurent Quero, MD, PhD, MS
Sunday, Oct 21
1:15 pm

SU_10_2094 - A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer
Location: Innovation Hub, Exhibit Hall 3
David Routman, MD
Sunday, Oct 21
1:15 pm

SU_10_2095 - Texture Analysis of FDG-PET/CT for Patients with Esophageal SCC Treated By Chemoradiotherapy
Location: Innovation Hub, Exhibit Hall 3
Noriyoshi Takahashi, MD, PhD
Sunday, Oct 21
1:15 pm

SU_10_2096 - Analysis of the Cardiovascular Complications After Definitive Chemoradiotherapy for Esophageal Cancer Using Biological Dose Volume Histogram
Location: Innovation Hub, Exhibit Hall 3
Yuki Takeuchi, MD
Sunday, Oct 21
1:15 pm

SU_10_2097 - Incidence of regional recurrence outside of radiation fields in patients with or without elective nodal irradiation for stage I middle thoracic esophageal cancer
Location: Innovation Hub, Exhibit Hall 3
Shintaro Tsuruoka, MD
Sunday, Oct 21
1:15 pm

SU_10_2099 - Adjuvant Chemotherapy Can Not Prolong the Survival in Patients with Advanced Esophageal Squamous Cell Carcinoma after Chemoradiation -Data from NCT01551589
Location: Innovation Hub, Exhibit Hall 3
Qifeng Wang, MD
Sunday, Oct 21
1:15 pm

SU_10_2100 - Changes in Cardiac Volume during Concurrent Chemoradiotherapy for Esophageal Cancer Based on Repeated Enhanced 4DCT
Location: Innovation Hub, Exhibit Hall 3
Xue Wang
Sunday, Oct 21
1:15 pm

SU_10_2101 - A Chinese Multi-Institutional Analysis of Three Dimensional Conformal Radiation or Intensity-Modulated Radiation Therapy for Non-Operated Localized Esophageal Squamous Cell Carcinoma in Definitive (Chemo)Radiation
Location: Innovation Hub, Exhibit Hall 3
Xin Wang, MD
Sunday, Oct 21
1:15 pm

SU_10_2102 - Predictors of Cardiac Toxicity in Operable Esophageal Cancer Patients Treated With or Without Chemoradiation.
Location: Innovation Hub, Exhibit Hall 3
Jacob Witt, MD
Sunday, Oct 21
1:15 pm

SU_11_2104 - Management of Clinical Stage T1N0M0 Esophageal Cancer
Location: Innovation Hub, Exhibit Hall 3
Andrew Yang, MD, MS – Yonsei Cancer Center
Sunday, Oct 21
1:15 pm

SU_11_2106 - Prognostic Impact of Systemic Inflammatory Markers in Esophageal Squamous Cell Carcinoma treated with Chemoradiation
Location: Innovation Hub, Exhibit Hall 3
Connie Yip, MB, ChB, FRCR
Sunday, Oct 21
1:15 pm

SU_11_2108 - Late Toxicities Differed Maximum Tolerated Dose Determined by Acute Toxicities: Reanalysis of a Phase I/II Trial of Dose Escalation in Unresectable Thoracic Esophageal Cancer by Simultaneous Integrated Boost
Location: Innovation Hub, Exhibit Hall 3
Wen Yu, MD, PhD – Fudan University Shanghai Cancer Center
Sunday, Oct 21
1:15 pm

SU_11_2109 - A Modified N Stage Method Considering Negative Lymph Node and Positive Lymph Node for Esophagus Cancer Evaluation
Location: Innovation Hub, Exhibit Hall 3
Jinling Zhang, MD
Sunday, Oct 21
1:15 pm

SU_11_2110 - Lack of validation of lymphopenia as a prognostic factor in esophageal cancer chemoradiation
Location: Innovation Hub, Exhibit Hall 3
Minsi Zhang, MD
Sunday, Oct 21
1:15 pm

SU_11_2111 - Failure Patterns after Radical Surgery of Thoracic Esophageal Squamous Carcinoma
Location: Innovation Hub, Exhibit Hall 3
Xiaofei Zhang, MD
Sunday, Oct 21
1:15 pm

SU_11_2113 - A Clinical Analysis of Systemic Chemotherapy Combined with Radiation Therapy for Advanced Gastric Cancer
Location: Innovation Hub, Exhibit Hall 3
Hong Dong
Sunday, Oct 21
1:15 pm

SU_11_2115 - A Prospective Phase I Study of Hypo-Fractionated Neoadjuvant Radiation Therapy for Locally Advanced Gastric Cancer
Location: Innovation Hub, Exhibit Hall 3
Ning Li, MD
Sunday, Oct 21
1:15 pm

SU_11_2116 - Using ¹⁸F-FDG PET/CT to Estimate the Length of Gross Tumor and Involvement of Lymph Nodes in Esophagogastric Junction Carcinoma
Location: Innovation Hub, Exhibit Hall 3
Chi-Luan Ma, MB
Sunday, Oct 21
1:15 pm

SU_12_2117 - Survival outcomes and prognostic factors for gastric cancer in the adjuvant setting: An analysis of the National Cancer Database.
Location: Innovation Hub, Exhibit Hall 3
Susanna Nguy, MD
Sunday, Oct 21
1:15 pm

SU_12_2118 - Stage-matched survival differences by ethnicity among Asian gastric cancer patients treated in the United States
Location: Innovation Hub, Exhibit Hall 3
Ryan Rhome, MD, PhD
Sunday, Oct 21
1:15 pm

SU_12_2119 - Patterns of Failure in Gastric Carcinoma After Radical Gastrectomy and the Implication of Target Definition in Post-Operative Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Shubei Wang
Sunday, Oct 21
1:15 pm

SU_12_2120 - Skeletal Muscle Depletion during Chemoradiotherapy and Radiomics Features As Prognostic Factors of Toxicity and Outcomes in Patients with Gastric Cancer
Location: Innovation Hub, Exhibit Hall 3
Wang Yang, MD
Sunday, Oct 21
1:15 pm

SU_12_2121 - Can Chemoradiotherapy Improve Survival After An R1 Resection for Gastric Cancer: A Retrospective Study of A Chinese Cohort
Location: Innovation Hub, Exhibit Hall 3
Meng-long Zhou, MD, PhD
Sunday, Oct 21
1:15 pm

SU_12_2122 - High-Dose Radiation in Liver-Directed Concurrent Chemoradiotherapy Is Effective for Locally Advanced BCLC Stage C Hepatocellular Carcinoma
Location: Innovation Hub, Exhibit Hall 3
Hwa Kyung Byun, MD
Sunday, Oct 21
1:15 pm

SU_12_2123 - Evaluating Safety and Dosimetry of SBRT following ⁹⁰Y for Hepatocellular Carcinoma
Location: Innovation Hub, Exhibit Hall 3
Shauna Campbell, DO, RT
Sunday, Oct 21
1:15 pm

SU_12_2124 - Hafnium Oxide Nanoparticles Activated By Radiation Therapy: An Innovative Approach for the Treatment of Liver Cancers
Location: Innovation Hub, Exhibit Hall 3
Enrique Chajon Rodriguez, MD, PhD
Sunday, Oct 21
1:15 pm

SU_12_2125 - Assessment of Online Adaptive MR-Guided SBRT of Liver Cancers
Location: Innovation Hub, Exhibit Hall 3
Nesrin Dogan, PhD
Sunday, Oct 21
1:15 pm

SU_12_2126 - Patterns of Failure and Need for Biliary Intervention Among Patients with Biliary Tract Cancers Treated With Definitive Surgery and Adjuvant Chemoradiation
Location: Innovation Hub, Exhibit Hall 3
Morgan Freret, MD, PhD
Sunday, Oct 21
1:15 pm

SU_13_2031 - Are All Colorectal Oligometastases Equal?
Location: Innovation Hub, Exhibit Hall 3
Sean O'Cathail, MD
Sunday, Oct 21
1:15 pm

SU_13_2127 - Outcomes After Stereotactic Body Radiation Therapy (SBRT) as a Bridging Modality to Liver Transplantation for Hepatocellular Carcinoma (HCC)
Location: Innovation Hub, Exhibit Hall 3
Rashi Garg, MD
Sunday, Oct 21
1:15 pm

SU_13_2128 - Evaluation of Post- Stereotactic Body Radiation Therapy Response Assessment for Hepatocellular Carcinoma: An Appraisal of RECIST, m-RECIST and WHO Criteria.
Location: Innovation Hub, Exhibit Hall 3
Devon Godfrey, PhD
Sunday, Oct 21
1:15 pm

SU_13_2129 - Safety of liver stereotactic body radiation therapy for hepatocellular carcinoma following transarterial radioembolization vs. transarterial chemoembolization
Location: Innovation Hub, Exhibit Hall 3
Camille Hardy, BS
Sunday, Oct 21
1:15 pm

SU_13_2130 - Effect of Treatment Schedule on Fatigue in Hepatocellular Carcinoma Patients Treated With Stereotactic Body Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Shaakir Hasan, DO
Sunday, Oct 21
1:15 pm

SU_13_2131 - Proton Therapy and the Role of Dosimetric Parameters as Predictors for Normal Tissue Complications after Liver-Directed Stereotactic Body Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Katharina Hoebel, MD
Sunday, Oct 21
1:15 pm

SU_13_2132 - Liver stereotactic body radiation therapy modulates systemic pharmacokinetics of sorafenib through p-glycoprotein
Location: Innovation Hub, Exhibit Hall 3
Chen-Hsi Hsieh, MD, PhD
Sunday, Oct 21
1:15 pm

SU_13_2133 - Proton beam therapy for unresectable cholangiocarcinoma
Location: Innovation Hub, Exhibit Hall 3
Sheng-Ping Hung, MD
Sunday, Oct 21
1:15 pm

SU_13_2134 - Predicting survival after liver SBRT by deep learning-based analysis of treatment dose plans
Location: Innovation Hub, Exhibit Hall 3
Bulat Ibragimov, PhD
Sunday, Oct 21
1:15 pm

SU_13_2136 - Comparison of Stereotactic Body Radiation Therapy Combined with or without Transcatheter Arterial Chemoembolization for Patients with Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies
Location: Innovation Hub, Exhibit Hall 3
Tomoki Kimura, MD, PhD
Sunday, Oct 21
1:15 pm

SU_14_2137 - Stereotactic Body Radiation Therapy for Centrally Located Hepatocellular Carcinoma: Outcomes and Toxicities
Location: Innovation Hub, Exhibit Hall 3
Stanislav Lazarev, MD – Mount Sinai Health System
Sunday, Oct 21
1:15 pm

SU_14_2138 - Skeletal Muscle Depletion Predicts the Prognosis of Patients with Hepatocellular Carcinoma Treated with Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Joon-gyo Lee
Sunday, Oct 21
1:15 pm

SU_14_2139 - Higher Risk Liver Stereotactic Body Radiation Therapy (SBRT): Treatment of Child-Pugh Class B and C Patients
Location: Innovation Hub, Exhibit Hall 3
Rebecca Levin-Epstein, MD, BS
Sunday, Oct 21
1:15 pm

SU_14_2140 - Prognostic Significance of Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma Patients after Radiation Therapy
Location: Innovation Hub, Exhibit Hall 3
Chenghsiang Lo, MD
Sunday, Oct 21
1:15 pm

SU_14_2141 - Functional Liver Image-Guided Hepatic Therapy (FLIGHT) with Hepatobiliary Iminodiacetic Acid (HIDA) Scans: Functional Parameters May Predict for Decompensation after Stereotactic Body Radiation Therapy (SBRT)
Location: Innovation Hub, Exhibit Hall 3
Ke (Colin) Huang, PhD, MS
Sunday, Oct 21
1:15 pm

SU_14_2142 - Clinical Outcomes Using Magnetic Resonance-Guided Stereotactic Body Radiation Therapy in Patients with Locally Advanced Cholangiocarcinoma
Location: Innovation Hub, Exhibit Hall 3
Elaine Luterstein, BS
Sunday, Oct 21
1:15 pm

SU_14_2143 - Dynamic Contrast Enhanced MRI Reveals Acute Changes in Vascular Permeability/Perfusion Following Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma
Location: Innovation Hub, Exhibit Hall 3
Eric Miller, MD, PhD
Sunday, Oct 21
1:15 pm

SU_14_2144 - Central Hepatobiliary Tree As an Organ at Risk for Stereotactic Body Radiation Therapy (SBRT) of the Liver: Is It High Priority for Hepatocellular Carcinoma (HCC)?
Location: Innovation Hub, Exhibit Hall 3
Ram Narayan, MD
Sunday, Oct 21
1:15 pm

SU_14_2145 - Value of Functional Liver Imaging in Heavily Pre-Treated Hepatocellular Carcinoma Patients
Location: Innovation Hub, Exhibit Hall 3
Stephanie Schaub, MD – University of Washington